

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID : SSSPTA1600RXA

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAplus - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:43:12 ON 08 DEC 2005

=> fil reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:43:22 ON 08 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 DEC 2005 HIGHEST RN 869534-51-0
DICTIONARY FILE UPDATES: 7 DEC 2005 HIGHEST RN 869534-51-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\106569071.str



chain nodes :

10 11 12 14 15 16

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

7-11 8-10 11-12 12-14 14-15 14-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-11 8-9 8-10 11-12 12-14 14-15

14-16


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 14:CLASS 15:CLASS 16:CLASS

Element Count :
Node 12: Limited
C,C4
N,N1
O,OO
S,SO





L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10656907.str



chain nodes :

10 11 12 14 15 16 26 27 28 29 30 31

ring nodes :

1 2 3 4 5 6 7 8 9 17 18 19 20 21 22 23 24 25

chain bonds :

7-11 8-10 11-12 12-14 14-15 14-16 23-27 24-26 27-28 28-29 29-30 29-31

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 17-18 17-22 18-19 19-20 20-21
21-22 21-23 22-25 23-24 24-25

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-11 8-9 8-10 11-12 12-14 14-15
14-16 17-18 17-22 18-19 19-20 20-21 21-22 21-23 22-25 23-24 23-27 24-25
24-26 27-28 28-29 29-30 29-31

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:Atom 29:CLASS
30:CLASS 31:CLASS

fragments assigned product role:

containing 1

fragments assigned reactant/reagent role:

containing 17

Element Count :

Node 12: Limited

C,C4


N,N1

O,O0

S,S0

L2 STRUCTURE UPLOADED

=> d
L2 HAS NO ANSWERS
L2 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 08:44:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5342 TO ITERATE

37.4% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 102458 TO 111222
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 08:44:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 107981 TO ITERATE

100.0% PROCESSED 107981 ITERATIONS
SEARCH TIME: 00.00.03
61 ANSWERS

L4 61 SEA SSS FUL L1

=> s 12
SAMPLE SEARCH INITIATED 08:44:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1606 TO ITERATE

100.0% PROCESSED 1606 ITERATIONS
SEARCH TIME: 00.00.01
30 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 29716 TO 34524
PROJECTED ANSWERS: 272 TO 928

L5 30 SEA SSS SAM L2

=> s 12 full
FULL SEARCH INITIATED 08:44:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 32848 TO ITERATE

100.0% PROCESSED 32848 ITERATIONS
SEARCH TIME: 00.00.02

698 ANSWERS

L6 698 SEA SSS FUL L2

=> s 14 and caplus/lc
49135313 CAPLUS/LC
L7 61 L4 AND CAPLUS/LC

=> s 16 and caplus/lc
49135313 CAPLUS/LC
L8 684 L6 AND CAPLUS/LC

=> s 16 not 18
L9 14 L6 NOT L8

=> d 19 1-14

L9 ANSWER 1 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 356069-63-1 REGISTRY

ED Entered STN: 12 Sep 2001

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C22 H24 Cl N5 O3

CI COM

SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 2 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 356069-56-2 REGISTRY

ED Entered STN: 12 Sep 2001

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C23 H24 N6 O3

CI COM

SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 3 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 356069-54-0 REGISTRY

ED Entered STN: 12 Sep 2001

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C22 H24 N5 O3

CI COM

SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 4 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 356069-52-8 REGISTRY

ED Entered STN: 12 Sep 2001

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C22 H24 F N5 O3

CI COM

SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 5 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 341031-32-4 REGISTRY

ED Entered STN: 12 Sep 2001

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl] (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C22 H24 Br N5 O3

CI COM

SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 6 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 341031-64-9 REGISTRY

ED Entered STN: 14 Jun 2001

CN Butanedioic acid, hydroxy-, (2S)-, compd. with

N-[2-(dimethylamino)ethyl]-

5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Pyrrole-3-carboxamide,

N-[2-(dimethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) (9CI)

FS STEREOSEARCH

MF C20 H23 F N4 O2 . C4 H6 O5


SR CAS Client Services

CM 1

CRN 326914-17-4

CMF C20 H23 F N4 O2

Double bond geometry as shown.




CM 2

CRN 97-67-6

CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



L9 ANSWER 7 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 341031-62-7 REGISTRY

ED Entered STN: 14 Jun 2001

CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) (9CI)

FS STEREOSEARCH

MF C20 H23 Br N4 O2 . C4 H6 O5


SR CAS Client Services

CM 1

CRN 326914-14-1

CMF C20 H23 Br N4 O2

Double bond geometry as shown.




CM 2

CRN 97-67-6

CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



L9 ANSWER 8 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 341031-61-6 REGISTRY

ED Entered STN: 14 Jun 2001

CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) (9CI)

FS STEREOSEARCH

MF C20 H23 Cl N4 O2 . C4 H6 O5


SR CAS Client Services

CM 1

CRN 326914-16-3

CMF C20 H23 Cl N4 O2

Double bond geometry as shown.




CM 2

CRN 97-67-6

CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).




L9 ANSWER 9 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN 341031-59-2 REGISTRY
ED Entered STN: 14 Jun 2001
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) (9CI)
FS STEREOSEARCH
MF C20 H24 N4 O2 . C4 H6 O5
SR CAS Client Services

CM 1

CRN 326914-19-6
CMF C20 H24 N4 O2


Double bond geometry as shown.



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).




L9 ANSWER 11 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN 341031-56-9 REGISTRY
ED Entered STN: 14 Jun 2001
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-((Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(diethylamino)ethyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) (9CI)
FS STEREOSEARCH
MF C22 H27 Br N4 O2 . C4 H6 O5
SR CAS Client Services

CM 1

CRN 326914-12-9
CMF C22 H27 Br N4 O2


Double bond geometry as shown.



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).




L9 ANSWER 10 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN 341031-57-0 REGISTRY
ED Entered STN: 14 Jun 2001
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-((Z)-(2-(diethylamino)ethyl)-5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) (9CI)
FS STEREOSEARCH
MF C22 H28 N4 O2 . C4 H6 O5
SR CAS Client Services

CM 1

CRN 326914-09-4
CMF C22 H28 N4 O2


Double bond geometry as shown.



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).




L9 ANSWER 12 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN 341031-55-0 REGISTRY
ED Entered STN: 14 Jun 2001
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-((Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(diethylamino)ethyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) (9CI)
FS STEREOSEARCH
MF C22 H27 Cl N4 O2 . C4 H6 O5
SR CAS Client Services

CM 1

CRN 326914-10-7
CMF C22 H27 Cl N4 O2


Double bond geometry as shown.



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



L9 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 326914-16-3 REGISTRY

ED Entered STN: 13 Mar 2001

CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C20 H23 Cl N4 O2

CI COM

SR CAS Client Services

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN 326914-14-1 REGISTRY

ED Entered STN: 13 Mar 2001

CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C20 H23 Br N4 O2

CI COM

SR CAS Client Services

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	358.05	358.26	

FILE 'CAPLUS' ENTERED AT 08:45:03 ON 08 DEC 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2005 VOL 143 ISS 24
 FILE LAST UPDATED: 7 Dec 2005 (20051207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 08:43:12 ON 08 DEC 2005)

FILE 'REGISTRY' ENTERED AT 08:43:22 ON 08 DEC 2005
 L1 STRUCTURE UPLOADED
 L2 STRUCTURE UPLOADED
 L3 0 S L1
 L4 61 S L1 FULL
 L5 30 S L2
 L6 698 S L2 FULL
 L7 61 S L4 AND CAPLUS/LC
 L8 684 S L6 AND CAPLUS/LC
 L9 14 S L6 NOT L8

FILE 'CAPLUS' ENTERED AT 08:45:03 ON 08 DEC 2005

=> s 18
 L10 94 L8

=> s 17
 L11 33 L7

=> s 18 and 17
 94 L8
 33 L7
 L12 18 L8 AND L7

=> d ibib abs hitstr 1-18

ACCESSION NUMBER: 2005:651441 CAPLUS

DOCUMENT NUMBER: 143:298470

TITLE: Indolin-2-ones with High in Vivo Efficacy in a Model for Multiple Sclerosis

AUTHOR(S): Bouerat, Laetitia; Fensholdt, Jef; Liang, Xifu; Havez, Sophie; Nielsen, Simon F.; Hansen, Jens R.

CORPORATE SOURCE: LEO Pharma A/S, Ballerup, DK-2750, Den.

SOURCE: Journal of Medicinal Chemistry (2005), 48(17), 5412-5414

CODEN: JMCHAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The known KDR inhibitor SU5416 and several analogs of the indolin-2-one family were surprisingly found to be highly efficacious in the EAE model, an established model for multiple sclerosis. The high in vivo effect could be correlated to in vitro inhibition of the pro-inflammatory cytokine IL-2. Activity following po administration was obtained with several analogs and via the use of prodrugs.


IT 280748-39-2P 856434-48-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Indolinones with High in Vivo Efficacy in a Model for Multiple Sclerosis)

RN 280748-39-2 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 856434-48-5 CAPLUS

CN 1H-Pyrrole-2-carboxamide,

5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-

N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:567120 CAPLUS

DOCUMENT NUMBER: 143:97259

TITLE: Preparation of indolinone derivatives as agents to prevent, treat and/or ameliorate multiple sclerosis.

INVENTOR(S): Bouerat, Laetitia Haud Elysa; Fensholdt, Jef;

Nielsen, Simon Feldbaek; Liang, Xifu; Havez, Sophie Elisabeth; Andersson, Ellen Christina; Jensen, Lene; Hansen, Jens

PATENT ASSIGNEE(S): Rainer

Leo Pharma A/S, Den.

SOURCE: PCT Int. Appl., 198 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058309	A1	20050630	WO 2004-DK875	20041216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, D2, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2003-529630P	P 20031216	

OTHER SOURCE(S): MARPAT 143:97259
GI

(Continued)



AB Title compds. I [R1-4 = H, halo, trihalomethyl, etc.; R5 = H, OH, alkyl, etc.; R6 = H, alkyl, cycloalkyl, etc.; A = Ph, mono/bicyclic heteroaryl, etc.; X = O, S] are prepared. For instance, II is prepared from 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid Et ester and 1,3-dihydroindol-2-one (EtOH, piperidine) in 99% yield. In an assay of exptl.-induced autoimmune encephalomyelitis (EAE) compds. of the invention, in particular, 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one (no exptl.), is shown to significantly inhibit EAE compared to dexamethasone; both compds. are known KDR kinase inhibitors. I are useful for the prevention, treatment or amelioration of multiple sclerosis, or to delay the onset of or reduce the relapse rate in multiple sclerosis.


IT 280748-39-2P, 4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of indolinone derivs. as agents to inhibit exptl.-induced autoimmune encephalomyelitis)

RN 280748-39-2 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-


ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




IT 342641-94-5P, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

L12 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 356068-91-28, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidene)methyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
 856434-48-58 856434-50-9P, 4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidene)methyl)-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)amide 856434-51-0P, 4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidene)methyl)-1H-pyrrole-2-carboxylic acid (2-methoxyethyl)amide 856434-52-1P, 4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidene)methyl)-1H-pyrrole-2-carboxylic acid [3-(1-formylpiperidin-4-yl)propyl]amide 856434-53-2P
 856434-54-3P 856434-55-4P 856434-56-5P
 856434-57-6P 856434-58-7P 856434-59-8P
 856434-60-1P 856434-61-2P 856434-62-3P
 856434-63-4P 856434-64-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of indolinone derivs. as agents to inhibit exptl.-induced autoimmune encephalomyelitis)

RN 342641-94-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylaminoethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-91-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylaminoethyl)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 856434-48-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)


L12 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 856434-50-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[2-(diethylaminoethyl)-5-[(2,3-dihydro-2-oxo-1H-indol-3-yl)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 856434-51-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 5-[(2,3-dihydro-2-oxo-1H-indol-3-yl)methyl]-N-(2-methoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 856434-52-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 5-[(2,3-dihydro-2-oxo-1H-indol-3-yl)methyl]-N-(3-(1-formyl-4-piperidinyl)propyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 856434-53-2 CAPLUS
 CN Butanoic acid, 4-[(5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


L12 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 856434-54-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 N-(6-hydroxyhexyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 856434-55-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-(cyclohexylmethyl)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 856434-56-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 N-(4-hydroxybutyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 856434-57-6 CAPLUS
 CN Hexanoic acid, 6-[(5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl)carbonyl]amino-, ethyl ester (9CI) (CA INDEX NAME)


L12 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 856434-58-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 4-methyl-N-(tetrahydro-2-furanyl)methyl- (9CI) (CA INDEX NAME)




RN 856434-59-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 N-(2-(1H-indol-3-yl)ethyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 856434-60-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 4-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 856434-61-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
S-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-
4-methyl-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)




RN 856434-62-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
S-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-
N-(5-hydroxypentyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 856434-63-4 CAPLUS
CN Butanoic acid, 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]amino-, ethyl ester (9CI) (CA INDEX NAME)



RN 856434-64-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[1-(4-chlorophenyl)cyclopropyl]methyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


ACCESSION NUMBER: 2005523281 CAPLUS
DOCUMENT NUMBER: 143:59818
TITLE: Preparation of 2-[(2-oxo-1,2-dihydro-indol-3-ylidene)methyl]pyrrole-4-carboxamide derivatives as protein kinase inhibitors
INVENTOR(S): Liang, Congxin
PATENT ASSIGNEE(S): The Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 54 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053686	A1	20050616	WO 2004-US39752	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, 2M, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2003-525430P	P	20031126
		US 2004-545721P	P	20040218


OTHER SOURCE(S): MARPAT 143:59818
GI



Q= -NR₆- (CHR₆)_n-[CH(OH)-(CHR₇)_m]p-COR₈




AB The title compds. (I) [wherein R1 = H, halo, Cl-6 alkyl, C3-8 cycloalkyl, sulfonamide, cyano, (un)substituted C6-10 aryl; R2 = H, halo, Cl-6 alkyl, C3-8 cycloalkyl, Cl-6 haloalkyl, HO, Cl-6 alkoxy, NH2, Cl-6 aikylamino, amide, alkylamino, C6-10 arylamino; R3 = H, Cl-6 alkyl, C6-10 aryl, C5-10 heteroaryl, amide; R4-R6 = H, Cl-6 alkyl; R7 = H, Cl-6 alkyl, HO; R8 = HO, Cl-6 alkoxy, C3-8 cycloalkoxy, NR9R10 (where R9, R10 = H, Cl-6 alkyl, Cl-6 hydroxalkyl, Cl-6 dihydroxalkyl, Cl-6 alkoxy, Cl-6 alkylcarboxylic acid, Cl-6 alkylphosphoric acid, Cl-6 alkylsulfuric acid, Cl-6 hydroxalkylcarboxylic acid, Cl-6 alkyl amide, C3-8 cycloalkyl, C5-8 heterocycloalkyl, C6-8 aryl, C5-8 heteroaryl, C3-8 cycloalkylcarboxylic acid; or NR9R10 together forms (un)substituted (C5-C8) heterocyclic]; n, m = 0-3; p = 1-3] or pharmaceutically acceptable salts, their tautomers, pharmaceutically acceptable salts of their tautomers, or prodrugs thereof are prepared. These compds. have enhanced and unexpected drug properties as inhibitors of protein kinases, in particular VEGF receptors and PDGF receptors, and are useful in treating disorders related to abnormal protein kinase activities such as cancer (no data). Thus, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidene)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid was condensed with (4R,6R)-[6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetyl acid tert-Bu ester using 3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazole in DMF at room temperature for 30 h followed by treatment with a mixture of 2 N aqueous HCl, THF, and EtOH, neutralization with aqueous NaHCO₃, extraction with Me tert-Bu ether to give (3R,5R)-7-[(5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidene)-2,4-dimethyl-1H-pyrrole-3-carboxyl)amino]-3,5-dihydroxyheptanoic acid tert-Bu ester which was stirred with a mixture of aqueous NaOH solution and MeOH at room temperature for 3 h to give (3R,5R)-7-[(5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidene)-2,4-dimethyl-1H-pyrrole-3-carboxyl)amino]-3,5-dihydroxyheptanoic acid sodium salt (II). IT 854269-49-1P 854269-51-5P 854269-52-6P 854269-53-7P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of ((oxodihydroindolylidene)methyl)pyrrolecarboxamide derivs. as protein kinase inhibitors)
RN 854269-49-1 CAPLUS
CN Heptanoic acid, 7-[[5-((2Z)-(5-fluoro-2-oxo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy-, monosodium salt, (3R,5R)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.
Double bond geometry as shown.



● Na


RN 854269-51-5 CAPLUS
CN Butanoic acid, 4-[(5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-3-hydroxy-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 854269-52-6 CAPLUS
CN Butanoic acid, 4-[(5-[(Z)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-3-hydroxy-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 854269-53-7 CAPLUS
CN D-erythro-Hexonic acid, 2,4,6-trideoxy-6-[(5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● Na


RN 854269-54-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-4-(4-morpholinyl)-4-oxobutyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 854269-55-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-4-(4-morpholinyl)-4-oxobutyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 854269-56-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-4-(4-methyl-1-piperazinyl)-4-oxobutyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)



● Na

IT 854269-50-4P 854269-54-BP 854269-55-9P
854269-56-0P 854269-57-1P 854269-58-2P
854269-59-3P 854269-60-6P 854269-61-7P
854269-62-8P 854269-63-9P 854269-64-0P
854269-65-1P 854269-66-2P 854269-67-3P
854269-68-4P 854269-69-5P 854269-70-8P
854269-71-9P 854269-72-0P 854269-73-1P
854269-74-2P 854269-75-3P 854269-76-4P
854269-77-5P 854269-79-7P 854269-80-0P
854269-81-1P 854269-82-2P 854269-83-3P
854269-84-4P 854269-85-5P 854269-86-6P
854269-87-7P 854269-88-8P 854269-89-9P
854269-90-2P 854269-91-3P 854269-92-4P
854269-93-5P 854269-94-6P 854269-95-7P
854269-96-8P 854269-97-9P 854269-98-0P
854269-99-1P 854270-00-1P 854270-01-2P
854270-02-3P 854270-03-4P 854270-04-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(oxidihydroindolylidene)methyl]pyrrolecarboxamide deriv.)

as protein kinase inhibitors)

RN 854269-50-4 CAPLUS


CN Heptanoic acid, 7-[(5-[(Z)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-3,5-dihydroxy-, monosodium salt, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-57-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-7-(dimethylamino)-3,5-dihydroxy-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-58-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-oxo-7-(1-pyrrolidinyl)heptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-59-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-(4-morpholinyl)-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-60-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-(4-methyl-1-piperazinyl)-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-A

PAGE 1-B




RN 854269-61-7 CAPLUS
CN Pyrrolidine, 1-(2,4,6-trideoxy-6-[(5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino)-D-erythro-hexonoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L12 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN Butanoic acid, 2-ethyl-4-[(5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 854269-66-2 CAPLUS
CN Heptanoic acid, 7-[(5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy- (9CI) (CA INDEX NAME)




RN 854269-67-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 854269-62-8 CAPLUS
CN Piperazine, 1-methyl-4-[(2,4,6-trideoxy-6-[(5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino)-D-erythro-hexonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-63-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-7-(ethylamino)-3,5-dihydroxy-7-oxoheptyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-64-0 CAPLUS
CN Morpholine, 4-[(2,4,6-trideoxy-6-[(5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl)amino)-D-erythro-hexonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-65-1 CAPLUS

RN 854269-68-4 CAPLUS
CN Heptanoic acid, 7-[(5-[(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy- (9CI) (CA INDEX NAME)




RN 854269-69-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 854269-70-8 CAPLUS
CN Heptanoic acid, 7-[(5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy-, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-71-9 CAPLUS
CN Heptanoic acid, 7-[(5-[(2)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino)-3,5-dihydroxy-, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-72-0 CAPLUS
CN D-erythro-Hexonic acid, 2,4,6-trideoxy-6-[(5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-73-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(7-amino-3,5-dihydroxy-7-oxoheptyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-74-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3,5-dihydroxy-7-(methylamino)-7-oxoheptyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 854269-75-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[7-(dimethylamino)-3,5-dihydroxy-7-oxoheptyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-76-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(7-(ethylamino)-3,5-dihydroxy-7-oxoheptyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 854269-77-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3,5-dihydroxy-7-[(1-methylethyl)amino]-7-oxoheptyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NHPr-1

RN 854269-79-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3,5-dihydroxy-7-oxo-7-(1-pyrrolidinyl)heptyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 854269-80-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3,5-dihydroxy-7-oxo-7-(1-piperidinyl)heptyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 854269-81-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[3,5-dihydroxy-7-(4-morpholinyl)-7-oxoheptyl]-
 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
 (9CI) (CA INDEX NAME)

PAGE 2-A




RN 854269-82-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[3,5-dihydroxy-7-(4-methyl-1-piperazinyl)-7-
 oxoheptyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-
 dimethyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 854269-83-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[3,5-dihydroxy-7-oxo-7-(1-piperazinyl)heptyl]-
 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
 (9CI) (CA INDEX NAME)

PAGE 2-A




RN 854269-84-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-(7-amino-3,5-dihydroxy-7-oxoheptyl)-5-[(4,5-
 difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)




RN 854269-85-5 CAPLUS


L12 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Pyrrole-3-carboxamide, 5-[(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-[3,5-dihydroxy-7-(methylamino)-7-oxoheptyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 854269-86-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-(4-amino-2-hydroxy-4-oxobutyl)-5-[(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-87-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-(4-amino-2-hydroxy-4-oxobutyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-88-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-4-(4-morpholinyl)-4-oxobutyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 854269-89-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-7-amino-3,5-dihydroxy-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 854269-90-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-oxo-7-(1-piperidinylheptyl)-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L12 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 854269-91-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-7-(cyclopentylamino)-3,5-dihydroxy-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 854269-92-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-(methylamino)-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 854269-93-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-[(1-methylethyl)amino]-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L12 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 854269-94-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-7-(diethylamino)-3,5-dihydroxy-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.




RN 854269-95-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(4-dimethylamino)-2-hydroxy-4-oxobutyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)





RN 854269-96-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[4-(ethylamino)-2-hydroxy-4-oxobutyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 854269-97-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-(4-(cyclopropylamino)-2-hydroxy-4-oxobutyl)-5-
{[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)




RN 854269-98-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-(4-(diethylamino)-2-hydroxy-4-oxobutyl)-5-{[5-
fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)




RN 854270-02-3 CAPLUS
CN D-erythro-Hexonamide, 2,4,6-trideoxy-N-ethyl-6-{{[5-[(Z)-(5-fluoro-1,2-
dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-
yl]carbonyl}amino}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 854270-03-4 CAPLUS
CN D-erythro-Hexonamide, 2,4,6-trideoxy-6-{{[5-[(Z)-(5-fluoro-1,2-dihydro-2-
oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl}amino}-
N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 854270-04-5 CAPLUS
CN D-erythro-Hexonamide, N-cyclopropyl-2,4,6-trideoxy-6-{{[5-[(Z)-(5-fluoro-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-
yl]carbonyl}amino}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 854269-99-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl}-N-(2-hydroxy-4-[(1-methylethyl)amino]-4-oxobutyl)-2,4-
dimethyl- (9CI) (CA INDEX NAME)




RN 854270-00-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl}-N-(2-hydroxy-4-oxo-4-(1-pyrrolidinyl)butyl)-2,4-dimethyl-
(9CI) (CA INDEX NAME)



RN 854270-01-2 CAPLUS
CN D-erythro-Hexonamide,
2,4,6-trideoxy-N,N-diethyl-6-{{[5-[(Z)-(5-fluoro-1,2-
dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-
yl]carbonyl}amino}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 356068-93-4P 854270-05-6P 854270-08-9P
854270-09-0P
RL RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of [(oxodihydroindolylidene)methyl]pyrrolecarboxamide
derivs.

as protein kinase inhibitors)


RN 356068-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-
3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 854270-05-6 CAPLUS
CN 1,3-Dioxane-4-acetic acid, 6-[2-{{[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl}amino}ethyl]-
2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 854270-08-9 CAPLUS
CN D-erythro-Hexonic acid,
2,4,6-trideoxy-6-{{[5-[(Z)-(5-fluoro-1,2-dihydro-2-
oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl}amino}-


L12 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 3,5-O-(1-methylethylidene)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 854270-09-0 CAPLUS
 CN Heptanoic acid, 7-[(5-((2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-3,5-dihydroxy-, 1,1-dimethylethyl ester, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 2-[(2-Oxo-1,2-dihydro-indol-3-ylidene)methyl]pyrrole-4-carboxamide derivs.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053614	A2	20050616	WO 2004-US39728	20041126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	US 2003-525430P	P	20031126
			US 2004-545721P	P 20040218

PRIORITY APPLN. INFO.: MARPAT 143:598016
 GI



Q= -NR6-(CHR6)n-[CH(OH)-(CHR7)m]p-COR8



L12 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 AB 2-[(2-Oxo-1,2-dihydro-indol-3-ylidene)methyl]pyrrole-4-carboxamide derivs.

(I) [wherein R1 = H, halo, Cl-6 alkyl, C3-8 cycloalkyl, Cl-6 haloalkyl, HO, Cl-6 alkoxy, NH2, Cl-6 alkylamino, amide, sulfonamide, cyano, (un)substituted C6-10 aryl; R2 = H, halo, Cl-6 alkyl, C3-8 cycloalkyl, Cl-6 haloalkyl, HO, Cl-6 alkoxy, C2-alkoxycarbonyl, NH2, Cl-6 alkylamino, C6-10 aryloxy; R3 = H, Cl-6 alkyl, C6-10 aryl, C5-10 heteroaryl, amide; R4-R6 = H, Cl-6 alkyl; R7 = H, Cl-6 alkyl, HO; R8 = HO, Cl-6 alkoxy, C3-8 cycloalkoxy, NR9R10 (where R9, R10 = H, Cl-6 alkyl, Cl-6 hydroxyalkyl, Cl-6 dihydroxyalkyl, Cl-6 alkoxy, Cl-6 alkylcarboxylic acid, Cl-6 alkylphosphoric acid, Cl-6 alkylsulfuric acid, Cl-6 hydroxylalkylcarboxylic acid, Cl-6 alkyl amide, C3-8 cycloalkyl, C5-8 heterocycloalkyl, C6-8 aryl, C5-8 heteroaryl, C3-8 cycloalkylcarboxylic acid; or NR9R10 together forms (un)substituted (C5-C8) heterocyclic); n, m = 0-3; p = 1-3] or pharmaceutically acceptable salts, their tautomers, pharmaceutically acceptable salts of their tautomer, or prodrugs thereof are prepared

These compds. have enhanced and unexpected drug properties as inhibitors of protein kinases, in particular VEGF receptors and PDGF receptors, and are useful in treating disorders related to abnormal protein kinase activities

such as cancer (no data). Thus, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid was condensed with (4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3dioxan-4-yl)acetic acid tert-Bu ester using 3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazole in DMF at room temperature for 30 min.

h followed by treatment with a mixture of 2 N aqueous HCl, THF, and EtOH, neutralization with aqueous NaHCO3, extraction with Me tert-Bu ether to give

(3R,5R)-7-[(5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino]-3,5-dihydroxyheptanoic acid sodium salt (II).


IT 854269-49-1P 854269-51-SP 854269-52-6P
 854269-53-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of [(oxodihydroindolylidene)methyl]pyrrolecarboxamide derivs. as protein kinase inhibitors)

RN 854269-49-1 CAPLUS
 CN Heptanoic acid, 7-[(5-((2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-3,5-dihydroxy-, monosodium salt, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L12 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● Na

RN 854269-51-5 CAPLUS
 CN Butanoic acid, 4-[(5-((2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-3-hydroxy-

(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 854269-52-6 CAPLUS
 CN Butanoic acid, 4-[(5-((2)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-3-hydroxy-

(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 854269-53-7 CAPLUS
 CN D-erythro-Hexonic acid, 2,4,6-trideoxy-6-[(5-((2)-(5-fluoro-1,2-dihydro-2-

oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



● Na

IT 854269-50-4P 854269-54-BP 854269-55-9P
 854269-56-0P 854269-57-1P 854269-58-2P
 854269-59-3P 854269-60-6P 854269-61-7P
 854269-62-8P 854269-63-9P 854269-64-0P
 854269-65-1P 854269-66-2P 854269-67-3P
 854269-68-4P 854269-69-5P 854269-70-6P
 854269-71-7P 854269-72-0P 854269-73-1P
 854269-74-2P 854269-75-3P 854269-76-4P
 854269-77-5P 854269-79-7P 854269-80-0P
 854269-81-1P 854269-82-2P 854269-83-3P
 854269-84-4P 854269-85-5P 854269-86-6P
 854269-87-7P 854269-88-8P 854269-89-9P
 854269-90-2P 854269-91-3P 854269-92-4P
 854269-93-5P 854269-94-6P 854269-95-7P
 854269-96-8P 854269-97-9P 854269-98-0P
 854269-99-1P 854270-00-1P 854270-01-2P
 854270-02-3P 854270-03-4P 854270-04-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of [(oxodihydroindolylidene)methyl]pyrrolecarboxamide derivs.
 as protein kinase inhibitors)
 RN 854269-50-4 CAPLUS
 CN Heptanoic acid, 7-[(5-(Z)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy-, monosodium salt, (3R,5R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



● Na


L12 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 oxoheptyl]-5-(Z)-5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 854269-58-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-oxo-7-(1-pyrrolidinyl)heptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 854269-59-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-(4-morpholinyl)-7-oxoheptyl]-5-(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 854269-60-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-(4-methyl-1-piperazinyl)-7-oxoheptyl]-5-(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


RN 854269-54-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-((Z)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-4-(4-morpholinyl)-4-oxobutyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 854269-55-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-4-(4-morpholinyl)-4-oxobutyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 854269-56-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-4-(4-methyl-1-piperazinyl)-4-oxobutyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 854269-57-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-7-(dimethylamino)-3,5-dihydroxy-7-




PAGE 1-B




RN 854269-61-7 CAPLUS
 CN Pyrrolidine,
 1-[2,4,6-trideoxy-6-[(5-(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-D-erythro-hexonoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 854269-62-8 CAPLUS
 CN Piperazine,
 1-methyl-4-[2,4,6-trideoxy-6-[[5-(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-D-erythro-hexonoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 854269-63-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,SR)-7-(ethylamino)-3,5-dihydroxy-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-64-0 CAPLUS
CN Morpholine, 4-[2,4,6-trideoxy-6-[[5-((2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-D-erythro-hexonoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-65-1 CAPLUS
CN Butanoic acid,
2-ethyl-4-[(5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 854269-69-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 854269-70-8 CAPLUS
CN Heptanoic acid, 7-[(5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy- (3R,SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-71-9 CAPLUS
CN Heptanoic acid, 7-[(5-((Z)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-



RN 854269-66-2 CAPLUS
CN Heptanoic acid, 7-[(5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy- (9CI) (CA INDEX NAME)




RN 854269-67-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 854269-68-4 CAPLUS
CN Heptanoic acid, 7-[(5-((4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy- (9CI) (CA INDEX NAME)


ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy-, (3R,SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-72-0 CAPLUS
CN D-erythro-Hexonic acid,
2,4,6-trideoxy-6-[(5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-73-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(7-amino-3,5-dihydroxy-7-oxoheptyl)-5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-74-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-(3,5-dihydroxy-7-(methylamino)-7-oxoheptyl)-5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-75-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide,
N-(7-(dimethylamino)-3,5-dihydroxy-7-oxoheptyl)-
5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

RN 854269-76-4 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[7-(ethylamino)-3,5-dihydroxy-7-oxoheptyl]-
5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

RN 854269-77-5 CAPLUS



CN 1H-Pyrrole-3-carboxamide, N-[3,5-dihydroxy-7-((1-methylethyl)amino)-7-
oxoheptyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-
dimethyl- (9CI) (CA INDEX NAME)

--NHPr_1


RN 854269-79-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3,5-dihydroxy-7-oxo-7-(1-pyrrolidinyl)heptyl]-
5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)



RN 854269-80-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide,
N-[3,5-dihydroxy-7-oxo-7-(1-piperidinyl)heptyl]-
5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)


RN 854269-82-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3,5-dihydroxy-7-(4-methyl-1-piperazinyl)-7-
oxoheptyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-
dimethyl- (9CI) (CA INDEX NAME)




RN 854269-81-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide,
N-[3,5-dihydroxy-7-(4-morpholinyl)-7-oxoheptyl]-


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 854269-83-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[{4,5-dihydroxy-7-oxo-1-(1-piperazinyl)heptyl}-5-{(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 854269-84-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[{7-amino-3,5-dihydroxy-7-oxoheptyl}-5-{(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-85-5 CAPLUS



RN 854269-89-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[{(3R,5R)-7-amino-3,5-dihydroxy-7-oxoheptyl}-5-{(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-90-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[{(3R,5R)-3,5-dihydroxy-7-oxo-7-(1-piperidinyl)heptyl}-5-{(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L12 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[{4,5-dihydroxy-7-(methylamino)-7-oxoheptyl}-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-86-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[{4-amino-2-hydroxy-4-oxobutyl}-5-{(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 854269-87-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[{4-amino-2-hydroxy-4-oxobutyl}-5-{(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-88-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[{4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[2-hydroxy-4-(4-morpholinyl)-4-oxobutyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-91-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-7-(cyclopropylamino)-3,5-dihydroxy-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-92-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-(methylamino)-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-3,5-dihydroxy-7-[(1-methylethyl)amino]-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-94-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3R,5R)-7-(diethylamino)-3,5-dihydroxy-7-oxoheptyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 854269-95-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-dimethylamino)-2-hydroxy-4-oxobutyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-96-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-ethylamino)-2-hydroxy-4-oxobutyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-97-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-(cyclopropylamino)-2-hydroxy-4-oxobutyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854269-98-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-(diethylamino)-2-hydroxy-4-oxobutyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 854269-99-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-4-(1-methylethyl)amino]-4-oxobutyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854270-00-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-4-(1-pyrrolidinyl)butyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 854270-01-2 CAPLUS
CN D-erythro-Hexanamide, 2,4,6-trideoxy-N,N-diethyl-6-[(5-(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-y]carbonylamino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854270-02-3 CAPLUS
CN D-erythro-Hexonamide, 2,4,6-trideoxy-N-ethyl-6-[[{5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854270-03-4 CAPLUS
CN D-erythro-Hexonamide, 2,4,6-trideoxy-6-[[{5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854270-04-5 CAPLUS
CN D-erythro-Hexonamide, N-cyclopropyl-2,4,6-trideoxy-6-[[{5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 356068-93-4P 854270-05-6P 854270-08-9P
854270-09-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [(oxodihydroindolylidene)methyl]pyrrolecarboxamide derivs.
as protein kinase inhibitors)
RN 356068-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 854270-05-6 CAPLUS
CN 1,3-Dioxane-4-acetic acid, 6-[2-[[{5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 854270-08-9 CAPLUS
CN D-erythro-Hexonic acid,
2,4,6-trideoxy-6-[[{5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-

Absolute stereochemistry.
Double bond geometry as shown.



RN 854270-09-0 CAPLUS
CN Heptanoic acid, 7-[[{5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy-1,1-dimethylethyl ester, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



TITLE: Preparation of indolinone derivatives and their use in treating disease-states such as cancer

INVENTOR(S): Arnaiz, Damian; Bryant, Judi; Chou, Yuo-Ling; Feldman,

Richard; Hrvatin, Paul; Islam, Imadul; Kochanny, Monica; Lee, Wheeseong; Polokoff, Mark; Yu, Hongyi; Yuan, Shendong

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: U.S. Pat. Appl. Publ., 63 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 200509041	A1	20050428	US 2004-972023	20041022
WO 2005040116	A2	20050506	WO 2004-US35262	20041022
WO 2005040116	A3	20050616		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	PRIORITY APPN. INFO.:		US 2003-514081P	P 20031024

OTHER SOURCE(S): MARPAT 142:430132
GI



AB 3-(2-Pyrrolylmethylene)indolinone derivs. (I) (R1 = H, alkyl, C(O)OR7, C(O)N(R7)2, each (un)substituted aryl, aralkyl, or heterocycl; R2 = alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, cyano, -R8-OR7, -R8-N(R7)2, -R8-C(O)OR7, -R8-C(O)N(R7)2, -R8-S(O)tN(R7)2, -R8-N(R7)S(O)RN(R7)2, -R8-N(R7)S(O)RN(R7)C(O)OR7, -R8-N(R7)C(O)R7, -R8-N(R7)S8-C(O)R7, -R8-N(R7)C(O)N(R7)2,


L12 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 -R8-(N(R7)C(O)-R9-N(R7)2, -R8-N(R7)-R9-C(O)N(R7)2, -R8-N(R7)C(O)-R8-N(R7)-R8-C(O)R7, -R8-N(R7)C(O)-R8-N(R7)-R8-C(O)-R8-N(R7)2, each
 (un)substituted heterocyclic or cyclic ureido group, etc.: (where t = 1 or 2) R3 is hydrogen, alkyl or aralkyl; R5 = H, alkyl, aryl, aralkyl, -C(O)R11, -S(O)2R11; R6 = alkyl, alkenyl, alkynyl, halo, haloalkyl, cyano, nitro, each (un)substituted aryl, aralkyl, or heterocyclyl, -R9-OR7,

-R8-C(O)OR7, -R8-C(O)NR7, -R8-C(O)R7, -R8-N(R7)2, -R8-N(R7)C(O)R7, -R8-C(O)R7-R9-N(R7)2, -R8-N(R7)C(O)N(R7)2, etc.: R7 = H, haloalkyl, each (un)substituted alkyl, aryl, aralkyl, heterocyclyl, or heterocyclicalkyl; R8 = a bond or a straight or branched alkylene chain; R11 = haloalkyl, each (un)substituted alkyl, aryl, aralkyl, heterocyclyl, or heterocyclicalkyl as a single stereoisomer, a mixt. of stereoisomers, a solvate or a polymorph or pharmaceutically acceptable salts thereof are prep'd. These compds. are useful in treating mammal having disease-states alleviated by the inhibition of phosphoinositide-dependent kinase-1 (PDK-1) activity. Thus, a soln. of 5-methoxyindolin-2-one (0.41 g) and 2-pyrorolecarboxaldehyde (0.25 g) in ethanol (5 mL) was treated with piperidine (0.05 g). The reaction mixt. was then heated to 85° for 3 h, cooled to ambient temp., and chromatographed on silica gel (12 g) using 3:1 hexane/ethyl acetate to give 5-methoxy-3-[(pyrrol-2-yl)methylene]indolin-2-one (0.48 g).


IT 850717-09-EP, 5-Aminosulfonyl-3-[(4-carboxy-3-methylpyrrol-2-yl)methylene]indolin-2-one 850717-10-1P, 5-Aminosulfonyl-3-[(3-methyl-4-[(3-(piperidin-1-yl)propyl)amino]carbonyl)pyrrol-2-ylmethylene]indolin-2-one 850717-38-3P, 5-Ureido-3-[(4-[(2-imidazol-4-yl)amino]carbonyl)pyrrol-2-ylmethylene]indolin-2-one 850717-39-4P, 5-Ureido-3-[(4-[(2-pyridin-4-ylethyl)amino]carbonyl)pyrrol-2-ylmethylene]indolin-2-one 850717-42-9P, 5-Ureido-3-[(4-[(3-pyrrolidin-1-yl)propyl)amino]carbonyl)pyrrol-2-ylmethylene]indolin-2-one 850717-43-0P, 5-Ureido-3-[(4-[(4-pyrrolidin-1-ylbutyl)amino]carbonyl)pyrrol-2-ylmethylene]indolin-2-one 850718-20-6P, 5-Ureido-3-[(4-carboxypyrrrol-2-yl)methylene]indolin-2-one 850718-21-7P, 5-Ureido-3-[(2-(morpholin-4-ylethyl)amino)carbonyl]pyrrol-2-ylmethylene]indolin-2-one 850718-22-8P, 5-Ureido-3-[(4-[(2-(pyridin-1-ylethyl)amino)carbonyl]pyrrol-2-yl)methylene]indolin-2-one 850718-23-9P, 5-Ureido-3-[(4-[(3-methyl-4-carboxypyrrrol-2-yl)methylene]indolin-2-one 850718-24-0P, 5-Ureido-3-[(3-methyl-4-carboxypyrrrol-2-yl)methylene]indolin-2-one 850718-25-1P, 5-Ureido-3-[(4-[(3-(piperidin-1-yl)propyl)amino]carbonyl)pyrrol-2-ylmethylene]indolin-2-one 850718-26-2P, 5-Ureido-3-[(4-[(2-dimethylaminoethyl)amino]carbonyl)pyrrol-2-ylmethylene]indolin-2-one 850718-27-3P,

5-Ureido-3-[(3-methyl-4-[(2-(piperidin-1-yl)ethyl)amino]carbonyl)pyrrol-2-ylmethylene]indolin-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (Preparation of indolinone derivs. as phosphoinositide-dependent kinase-1 inhibitors for treating cancer)
 RN 850717-09-8 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)


L12 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 850717-10-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 850717-38-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-(aminocarbonyl)amino)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




L12 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 850717-39-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-(aminocarbonyl)amino)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 850717-42-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-(aminocarbonyl)amino)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 850717-43-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-(aminocarbonyl)amino)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)


L12 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 850718-20-6 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-(aminocarbonyl)amino)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 850718-21-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-(aminocarbonyl)amino)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 850718-22-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[5-(aminocarbonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 850718-23-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[5-(aminocarbonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 850718-24-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[5-(aminocarbonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-4-methyl- (9CI) (CA INDEX NAME)


L12 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 850718-25-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[5-(aminocarbonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 850718-26-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[5-(aminocarbonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 850718-27-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[5-(aminocarbonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-4-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L12 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005-2190 CAPLUS
DOCUMENT NUMBER: 142:93676
TITLE: A preparation of sulfonamide substituted indolinones, useful as inhibitors of DNA dependent protein kinase (DNA-PK)
INVENTOR(S): Howlett, Anthony R.; Rice, Audie; Moshinsky, Deborah; Hammarsten, Olle
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004266843	A1	20041230	US 2004-793943	20040308
PRIORITY APPLN. INFO.:			US 2003-452549P	P 20030307

OTHER SOURCE(S): MARPAT 142:93676
GI



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of sulfonamide substituted indolinones of formula I [wherein: R1 and R2 are independently selected from H, (un)substituted Ph, thiazolyl, or alkyl, etc.; R3, R4, and R5 are independently selected from H or alkyl], useful as inhibitors of DNA dependent protein kinase (DNA-PK). The invention relates to the field of radiosensitizing agents which are capable of enhancing radiotherapy by inhibiting DNA-PK (DNA-protein kinase). For instance, sulfonamide substituted indolinone II was prepared via condensation of pyrrole derivative III and indole derivative IV. The prepared indolinone derivative V was found to inhibit DNA-PK (IC50 = 1.6 μ M).
IT 342641-63-8 775321-58-9 775321-59-0P
775321-60-3P 775321-61-4P 775321-62-5P
775321-63-6P 775321-64-7P 775321-69-2P
775321-77-2P 775321-78-3P 775321-80-7P
775321-81-8P 910044-92-3P
PL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of sulfonamide substituted indolinones useful as inhibitors of DNA dependent protein kinase (DNA-PK))
RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)





RN 775321-58-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-5-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-60-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-5-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-59-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-61-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(Z)-(5-(2,3-dihydro-1H-indol-1-yl)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-62-5 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(Z)-5-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-63-6 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(Z)-5-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-64-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(Z)-(5-(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-69-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-5-[(2,3-dihydro-5-methoxy-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



NET_2


RN 775321-77-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L12 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Pyrrole-3-carboxamide,
 S-[(2)-[5-(2,3-dihydro-1H-indol-1-yl)sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-80-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(2)-[5-(2,3-dihydro-1H-indol-1-yl)sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-ethyl-4-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-81-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(2)-[5-(2,3-dihydro-1H-indol-1-yl)sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L12 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 819044-92-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-(3-ethylpentyl)-5-[(2)-[5-(5-fluoro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-B

L12 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ACCESSION NUMBER: 2004-818170 CAPLUS
 DOCUMENT NUMBER: 141:366237
 TITLE: Preparation of indolinone compounds for treatment of excessive osteolysis
 INVENTOR(S): Murray, Leesley; O'Farrell, Anne-Marie; Abrams, Tinya
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 34 pp.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 200409937	A1	20040121	US 2004-780917	20040219
CA 2516786	AA	20040910	CA 2004-2516786	20040223
WO 2004075775	A2	20040910	WO 2004-US5283	20040223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NR, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SE, SG, SI, SL, SV, TJ, TM, TN, TT, TZ, UA, UC, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UC, ZM, ZW, AM, AZ, BY, KG, KZ, ND, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

WO 2004075775	A2	20040910	WO 2004-US5283	20040223
WO 2004075775	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NR, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SE, SG, SI, SL, SV, TJ, TM, TN, TT, TZ, UA, UC, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UC, ZM, ZW, AM, AZ, BY, KG, KZ, ND, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1599207	A2	20051130	EP 2004-713728	20040223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: US 2003-448861P				P 20030224

US 2004-780917 A 20040219
 WO 2004-US5283 W 20040223

OTHER SOURCE(S): MARPAT 141:366237
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed is a method for treating excessive osteolysis in a patient, comprising administering to said patient an effective amount of a compound of

L12 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 formula (I) [wherein R = H, OH, alkyl, aryl, cycloalkyl, heterocycl, alkoxy, heterocycl, cycloalkyl, heteroaryl, heterocycl, HO, COR8, NR9R10, NR9COR10, CONPR10, R2 = alkyl, aryl, heterocycl, NR9R10, alkoxyl; R5 = H, alkyl, aryl, haloalkyl, cycloalkyl, heterocycl, heterocycl, heterocycl, HO, COR8, (CHR)nR11; X = O, S, p, n = 0-3, q = 0-2, wherein R8 = OH, alkyl, aryl, heterocycl, alkoxy, cycloalkyl, heterocycl, R9, R10 = H, alkyl, aryl, heterocycl, alkoxy, cycloalkyl, heterocycl; or NR9R10 together forms a ring consisting of the ring atoms selected from the group consisting of C, N, O, and S; R11 = OH, NH2, mono- or disubstituted amino, alkyl, aryl, heterocycl, alkoxy, cycloalkyl, heterocycl; R12 = OH, O-alkyl, aryl, heterocycl, alkoxy, cycloalkyl, heterocycl, R13 = alkyl, aryl, heterocycl, cycloalkyl, heterocycl; or NR9R14 forms a ring consisting of the ring atoms selected from the group consisting of CH2, N, O, and S; Q = C, N;

n = 0-4; m = 0-3] or salts thereof. These compds. are useful for treating excessive osteolysis, by inhibiting M-CSF mediated osteoclast development.

They are useful for inhibiting phosphorylation of colony-stimulating factor-1 receptor (CSF1R), and for treating cancers that express CSF1R. Thus, in a study on bone metastasis of cancer, 5-(5-fluoro-2-oxo-2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dieethylaminoethyl)amide (I) at 80 or 40 mg/kg per day for 21 days inhibited the growth of 4T1-HAL-luc breast cancer cells in bone by 89% in mice in 41 days after inoculation with cancer cells. Formulations, e.g. hard gelatin capsule contg. I, were described.


IT 356069-93-4P, (2Z)-3-[(3,5-Dimethyl-4-carboxy-1H-pyrrol-2-yl)methylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one 356069-08-4P
 RL: RCT (Reactant); SPA (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of indolinone compds. for treatment of excessive


osteolysis, inhibiting phosphorylation of colony-stimulating factor-1 receptor (CSF1R), and treating cancers that express CSF1R)

RN 356069-93-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, S-[(2)-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-08-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT 356068-94-5P 356068-97-8P, 5-[(Z)-5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylaminoethyl)amide 452104-42-6P, 5-[(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-(3-diethylamino-2-hydroxypropyl)amide 452104-85-7P,

5-[(Z)-5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-hydroxy-3-(morpholin-4-yl)propyl]amide 452104-86-8P, 2,4-Dimethyl-5-[(Z)-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrole-3-carboxylic acid [2-hydroxy-3-(morpholin-4-yl)propyl]amide 452104-87-9P, 5-[(Z)-5-Chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(morpholin-4-yl)propyl]amide 452104-88-0P,

5-[(Z)-5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(morpholin-4-yl)propyl]amide 452104-89-1P, 2,4-Dimethyl-5-[(Z)-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(morpholin-4-yl)propyl]amide 452104-90-4P,

5-[(Z)-5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(1H-[1,2,3]triazol-1-yl)propyl]amide 452104-91-5P, 5-[(Z)-5-Chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(1H-[1,2,3]triazol-1-yl)propyl]amide 452104-92-6P, 5-[(Z)-5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(1H-[1,2,3]triazol-1-yl)propyl]amide 452105-23-6P, 5-[(Z)-5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2(hydroxy-3-(morpholin-4-yl)propyl]amide 452105-24-7P 499220-14-3P 557795-19-4P, 5-[(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-diethylaminoethyl]amide 507879-12-7P, (Z)-5-[(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide

RL: PRAC (Pharmacological activity); SRN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of indolinone compds. for treatment of excessive osteosclerosis, inhibiting phosphorylation of colony-stimulating factor-1 receptor (CSF1R), and treating cancers that express CSF1R)

RN 356068-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)

NAME)


Double bond geometry as shown.



RN 356068-97-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylaminoethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-42-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-85-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-hydroxy-3-(4-morpholinyl)propyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-86-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-87-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-88-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-89-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-90-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-91-5 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-92-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[{(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[{(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





RN 587879-12-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 356069-06-2, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 356069-10-8,
(Z)-3-[{(3,5-Dimethyl-4-carboxy-1H-pyrrol-2-yl)methylen]-1,3-dihydro-2H-indol-2-one 356069-14-2, (Z)-3-[{(3,5-Dimethyl-4-carboxy-1H-pyrrol-2-yl)methylen]-5-chloro-1,3-dihydro-2H-indol-2-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of indolinone compds. for treatment of excessive osteolysis, inhibiting phosphorylation of colony-stimulating factor-1 receptor (CSF1R), and treating cancers that express CSF1R)
RN 356069-06-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[{(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 499220-14-3 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[{(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 342641-94-5
CMI C22 H27 F N4 O2



CM 2

CRN 97-67-6
CMI C4 H6 O5

Absolute stereochemistry. Rotation (-).




RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[{(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


RN 356069-10-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[{(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-14-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[{(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L12 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:857170 CAPLUS
 DOCUMENT NUMBER: 141:350032
 TITLE: Preparation of 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
 INVENTOR(S): Tang, Peng Chou Liang; Congxin; Miller, Todd; Lipson, Kenneth E.
 PATENT ASSIGNEE(S): Sugen Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 58 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PRIORITY APPLN. INFO.: US 2004204407 A1 20040114 US 2004-793952 P 20040308
 PRIORITY APPLN. INFO.: US 2003-452552 P 20030307

OTHER SOURCE(S): MARPAT 141:350022
 GI



I




II


AB The title compds. [I; R1 and R2 combine to form (un)substituted optionally fused heterocyclic ring; R3-R5 = H, alkyl, hydroxalkyl, etc.; or R3 and R4 may combine to form a cyclic 6-membered alicyclic ring which may be substituted with one or more lower alkyl] that modulate the activity of protein kinases ("PKs") and are therefore useful in treating disorders related to abnormal PK activity (no biol. data), were prepared. General method of synthesis of the compds. I by condensation of oxindoles and aldehydes (preparation of intermediates is given) is described. Eighty-two compds. I (e.g., II) were prepared. Pharmaceutical compns. comprising the

L12 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 775321-60-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-5-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-61-4 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(Z)-5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L12 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 compds. I, methods of treating diseases utilizing pharmaceutical compns. comprising these compds. and methods of prep. them are also disclosed.
 IT 775321-58-9P 775321-59-0P 775321-60-3P
 775321-61-4P 775321-62-5P 775321-63-6P
 775321-64-7P 775321-69-2P 775321-77-2P
 775321-78-3P 775321-80-7P 775321-81-8P
 775322-01-5P
 RL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 5-sulfonamido-substituted indolinone compds. as protein kinase inhibitors)

RN 775321-58-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-5-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

RN 775321-59-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-5-[(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L12 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 775321-62-5 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(Z)-5-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-63-6 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(Z)-5-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-64-7 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(Z)-5-[(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-69-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2,3-dihydro-5-methoxy-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—NET₂

RN 775321-77-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 775321-78-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, S-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 775321-80-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, S-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-ethyl-4-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 775321-81-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, S-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 775322-01-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(5-fluoro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ACCESSION NUMBER: 20041452964 CAPLUS

DOCUMENT NUMBER: 1411206

TITLE: Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders

INVENTOR(S): Abrams, Tinya; Murray, Lesley; Pryer, Nancy; Cherrington, Julie M.

PATENT ASSIGNEE(S): Sugan, Inc., USA

SOURCE: PCT Int. Appl., 87 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045523	A2	20040603	WO 2003-US36526	20031114
WO 2004045523	A3	20040530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KG, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MW, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VG, VN, YD, ZA, ZN, ZW
RW: BM, GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,

TG	NL 1024779	A1	20040518	NL 2003-1024779	20031114
	NL 1024779	C2	20041109		

CA 2506308	AA	20040603	CA 2003-2506308	20031114
------------	----	----------	-----------------	----------

US 2004152759	A1	20040805	US 2003-712296	20031114
---------------	----	----------	----------------	----------

EP 1562600	A2	20050817	EP 2003-783527	20031114
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
---	--	--	--	--

BR 2003015630	A	20050823	BR 2003-15630	20031114
---------------	---	----------	---------------	----------


NO 2005002578	A	20050527	NO 2005-2578	20050527
---------------	---	----------	--------------	----------

PRIORITY APPLN. INFO.: US 2002-426386P			P 20021115	
--	--	--	------------	--

WO 2003-US36526			W 20031114	
-----------------	--	--	------------	--

OTHER SOURCE(S): MARPAT 1411206

GI



AB The invention relates to a method of treating cancer by administering a combination of an indolinone compound with another chemotherapeutic agent.

The combination of an indolinone compound I (R = H, OH, alkyl, aryl, cycloalkyl, heteroaryl, alkoxy, heterocycle, amino; R1 = alkyl, halo, alkoxy, etc.; R2 = alkyl, aryl, heteroaryl, etc.; R5 = H, alkyl, aryl, haloalkyl, cycloalkyl, etc.; X = O, S; p = 0, 1, 2, 3; q = 0, 1, 2; Z = OH, -O-alkyl, -NR3R4; R3, R4 = H, alkyl, aryl, heteroaryl, cycloalkyl, heterocycle, or together with N form a ring) with another chemotherapeutic

agent provides an enhanced effect in treating cancer patients. Mice implanted with MX-1 human breast carcinoma fragments were treated with docetaxel and 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (preparation given).

IT 627908-92-3P 674778-85-9P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(as indolinone compound; cancer therapy using combination

administration of indolinone compds. with chemotherapeutic agents for cell proliferation disorders)

RN 627908-92-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 674778-85-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-



RN 346405-32-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 342641-94-5 342641-94-5D, acceptable salts, solvates, hydrates 346405-32-1D, acceptable salts, solvates, hydrates 356069-16-4 356069-16-4D, acceptable salts, solvates, hydrates 452104-43-7 452104-43-7D, acceptable salts, solvates, hydrates 452104-45-9 452104-45-9D, acceptable salts, solvates, hydrates 515138-82-6 515138-82-6D, acceptable salts, solvates, hydrates 627908-92-3D, acceptable salts, solvates, hydrates 674778-85-9D, acceptable salts, solvates, hydrates 697224-82-1

RL BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as indolinone compound; cancer therapy using combination administration of indolinone compds. with chemotherapeutic agents for cell proliferation disorders)


RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[(2-(diethylamino)ethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[(2-(diethylamino)ethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-16-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[(2-(diethylamino)ethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-16-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[(2-(diethylamino)ethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-43-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2-hydroxy-3-(4-morpholinyl)propyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-43-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)




RN 452104-45-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)




RN 452104-45-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)



RN 515138-82-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI)
 (CA INDEX NAME)




RN 515138-82-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI)
 (CA INDEX NAME)




RN 627908-92-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 674778-85-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2R]-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 697224-82-1 CAPLUS
 CN Butanedioic acid, hydroxy-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI)
 (CA INDEX NAME)


CM 1

CRN 342641-94-5
 CMF C22 H27 F N4 O2



CM 2


CRN 6915-15-7
 CMF C4 H6 O5



IT 356069-06-2, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 356069-08-4, 5-(2-Oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 356069-10-0, 356069-14-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(cancer therapy using combination administration of indolinone compds. with chemotherapeutic agents for cell proliferation disorders)


RN 356069-06-2 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-08-4 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-10-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-14-2 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


L12 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-85-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-86-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-87-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

Double bond geometry as shown.




IT 356068-93-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cancer therapy using combination administration of indolinone compds. with chemotherapeutic agents for cell proliferation disorders)

RN 356068-93-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 356068-97-8P, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid

(2-ethylaminoethyl)amide 452104-42-6P 452104-85-7P

452104-86-8P 452104-87-9P 452104-88-0P

452104-89-1P 452104-90-4P 452104-91-5P


452104-92-6P 452105-23-6P 452105-24-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(cancer therapy using combination administration of indolinone compds. with chemotherapeutic agents for cell proliferation disorders)


RN 356068-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylaminoethyl)-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-42-6 CAPLUS



RN 452104-88-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-89-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-90-4 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-91-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-92-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-((2S)-2-hydroxy-3-(4-morpholinyl)propyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



ACCESSION NUMBER: 2003:34853 CAPLUS

DOCUMENT NUMBER: 138:331677

TITLE: Treatment of acute myeloid leukemia with indolinone compounds, and preparation thereof

INVENTOR(S): O'Farrell, Ann-Marie; Cherrington, Julie

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FACTORY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035009	A2	20030501	WO 2002-US34525	20021028
WO 2003035009	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, T2, UA, UG, US, U2, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, C2, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2464790	AA	20030501	CA 2002-2464790	20021028
US 2002103280	A1	20030710	US 2002-281266	20021028
EP 1446117	A2	20040818	EP 2002-795563	20021028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013960	A	20040831	BR 2002-13960	20021028
JP 2005511540	T2	20050428	JP 2003-537578	20021028
ZA 200403091	A	20050114	ZA 2004-3091	20040422
PRIORITY APPLN. INFO.:			US 2001-330623P	P 20011026
			WO 2002-US34525	W 20021028

OTHER SOURCE(S): MARPAT 138:331677
GI



AB A method of treating acute myeloid leukemia in patient pos. for FLT-3-ITD

L12 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
is described. The treatment is accomplished by administration of an indolinone compd. (Markush included). Prepn. of the compds. of the invention, e.g., I, is described.

IT 342641-94-5P 346405-32-1P 356068-97-8P


452104-85-7P 452104-87-9P 452105-23-6P

452105-24-7P 515138-82-6P 557795-19-4P

RL: PA (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Indolinone derivative preparation for treatment of acute myeloid leukemia).


RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-97-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-85-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-87-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-23-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

Double bond geometry as shown.



IT 499220-14-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (indolinone derivative preparation for treatment of acute myeloid leukemia)
 RN 499220-14-3 CAPLUS
 CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylaminoethyl)-5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 342641-94-5
 CMF C22 H27 F N4 O2


CM 2

CRN 97-67-6
 CMF C4 H6 O5


Absolute stereochemistry. Rotation (-).




IT 356069-93-4 356069-10-8 356069-14-2
 468745-41-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (indolinone derivative preparation for treatment of acute myeloid leukemia)



RN 452105-24-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 515138-82-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 557795-19-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


RN 356069-93-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-10-8 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-14-2 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 468745-41-7 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 452104-42-6P 452104-86-8P 452104-88-0P
452104-89-1P 452104-90-4P 452104-91-5P
452104-92-6P


RL: SPN (Synthetic preparation); PREP (Preparation)
(indolinone derivative preparation for treatment of acute myeloid
leukemia)
RN 452104-42-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-
fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)



RN 452104-86-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 452104-88-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 452104-89-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-90-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-91-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-92-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



ACCESSION NUMBER: 2003:154170 CAPLUS

DOCUMENT NUMBER: 138:180703

TITLE: Combination therapy for the treatment of cancer

INVENTOR(S): Doshi, Parul; Cherrington, Julie

PATENT ASSIGNEE(S): Masferrer, Jaime, USA; Sugen Inc.

SOURCE: PCT Int. Appl., 217 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015608	A2	20030227	WO 2002-US25797	20020815
WO 2003015608	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, U2, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457745	AA	20030227	CA 2002-2457745	20020815
US 2003216410	A1	20031120	US 2002-218910	20020815
BR 2002011978	A	20040720	BR 2002-11978	20020815
CN 1541098	A	20041027	CN 2002-815912	20020815
JP 2005501843	T2	20050120	JP 2003-520373	20020815
NZ 530792	A	20050930	NZ 2002-530792	20020815
ZA 2004000849	A	20050503	ZA 2004-849	20040202
NO 2004000516	A	20040413	NO 2004-516	20040204
PRIORITY APPLN. INFO.:			US 2001-312413P	P 20010815
			WO 2002-US25797	W 20020815

OTHER SOURCE(S): MARPAT 138:180703
GI



AB: The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2

L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 SELECTIVE INHIBITORS. The protein kinase inhibitors are of the formula I where R = H, piperazin-1-ylmethyl, 4-methylpiperazin-1-ylmethyl, piperidin-1-ylmethyl, etc.; R1 = H, halo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, etc.; R2 = hydrogen, halo, alkyl, substituted alkyl, trihalomethyl, hydroxy, alkoxy, etc.; R3 = H, halogen, alkyl, substituted alkyl, trihalomethyl, hydroxy, alkoxy, aryl, heteroaryl, etc.; R4 = H, halogen, alkyl, substituted alkyl, hydroxy, alkoxy, etc.; R5 = H, alkyl, substituted alkyl, etc.; R6 = hydrogen, alkyl, substituted alkyl, etc.; and R7 = H, alkyl, substituted alkyl, aryl, heteroaryl, etc.


IT 356068-97-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); USES (Uses); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); COMBINATION THERAPY FOR TREATMENT OF CANCER USING PROTEIN TYROSINE KINASE INHIBITORS AND CYCOLOXYGENASE-2 INHIBITORS)

RN 356068-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 280748-39-2P, 4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid 342641-15-0P 342641-17-2P
 342641-18-3P 342641-19-4P 342641-20-7P
 342641-21-8P 342641-22-9P 342641-23-0P
 342641-24-1P 342641-24-2P 342641-26-3P
 342641-27-4P 342641-28-5P 342641-33-2P
 342641-35-4P 342641-36-5P 342641-37-6P
 342641-38-7P 342641-39-8P 342641-40-1P
 342641-41-2P 342641-42-3P 342641-43-4P
 342641-44-5P 342641-45-6P 342641-46-7P
 342641-47-8P 342641-48-9P 342641-49-0P
 342641-50-1P 342641-51-2P 342641-52-5P
 342641-54-7P 342641-55-8P 342641-56-9P
 342641-57-0P 342641-59-2P 342641-60-5P
 342641-61-6P 342641-62-7P 342641-63-8P
 342641-64-9P 342641-65-0P 342641-66-1P
 342641-67-2P 342641-68-3P 342641-69-4P
 342641-70-7P 342641-71-8P 342641-72-9P,
 2,4-Dimethyl-5-(2-oxo-6-phenyl-2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide
 342641-73-0P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide
 342641-74-1P, 5-[(3,5-Dichlorophenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 (2-diethylaminoethyl)amide 342641-75-2P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342641-76-3P

L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (2-diethylaminoethyl)-amide 356069-99-0P, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid


acid

(2-diethyl-N-oxoaminoethyl)-amide 356069-03-9P
 356069-04-0P 356069-05-1P 356069-07-3P
 356069-09-5P, 5-(2-Oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(3,5-dimethylpiperazin-1-yl)ethyl)amide
 356069-12-0P 356069-13-1P,
 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 356069-18-3P, 5-[5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 (2-(3,5-dimethylpiperazin-1-yl)ethyl)amide 356069-24-4P
 356069-25-5P 356069-26-6P 356069-36-8P
 356069-37-9P 356069-38-0P 356069-39-1P
 356069-40-4P 356069-41-5P 356069-42-6P
 356069-43-7P 356069-44-8P 356069-45-9P
 356069-46-0P 356069-47-1P 356069-48-2P
 356069-49-3P 356069-50-6P 356069-51-7P
 356069-53-9P 356069-55-1P 356069-57-3P
 356069-58-4P 356069-59-5P 356069-60-6P
 356069-61-9P 356069-62-0P 356069-64-2P
 356069-65-3P 356069-66-4P 356069-77-7P
 557795-19-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); COMBINATION THERAPY FOR TREATMENT OF CANCER USING PROTEIN TYROSINE KINASE INHIBITORS AND CYCOLOXYGENASE-2 INHIBITORS)

RN 280748-39-2 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 342641-15-0 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 342641-17-2 CAPLUS



L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

342641-77-4P, 2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide 342641-78-5P, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide 342641-79-6P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide 342641-81-0P, 3-[4-(3-Diethylaminopropyl)carbamoyl]-3,5-dimethyl-1H-pyrrol-2-ylmethylen]-2-carboxylic acid (3-chloro-4-methoxyphenyl)amide 342641-82-1P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide 342641-83-2P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342641-84-3P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide 342641-85-4P 342641-87-6P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)-amide 342641-88-7P 342641-89-8P,


5-[6-(Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide 342641-91-2P 342641-92-3P, 5-(6-(2,4-Dimethoxyphenyl)-2-

oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide 342641-93-4P,
 5-(6-(3-Isopropylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide 342641-95-6P, 3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide 342641-96-7P, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide 342641-97-8P 342641-98-9P
 ,2,4-Dimethyl-5-(2-oxo-5-(pyridin-3-ylsulfonyl)-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide 342642-01-7P, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342642-02-8P, 5-(5-(3-Chlorophenyl)sulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide 342642-03-9P
 4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid 342642-10-8P 342642-11-9P
 342642-12-0P, 5-Methyl-2-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid 342642-15-3P,
 2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid 342642-16-4P 342642-17-5P,
 2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide 356068-82-1P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide 356068-90-1P 356068-91-2P, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide 356068-92-3P, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ethyl)amide 356068-95-6P, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)-amide 356068-96-7P, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid


L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-19-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-20-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-21-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(2-diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 342641-22-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-(diethylamino)ethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 342641-23-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 342641-24-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-25-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(3-(diethylamino)propyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-26-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-27-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-28-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-33-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-35-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-36-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-37-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-38-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-39-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-40-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)





RN 342641-41-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-42-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-43-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 342641-48-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(4-hydroxyphenyl)ethyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-49-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-50-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


RN 342641-44-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-45-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-hydroxypropyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-46-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-47-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-51-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-52-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-54-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl] (9CI) (CA INDEX NAME)




RN 342641-55-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl] (9CI) (CA INDEX NAME)




RN 342641-56-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl (9CI) (CA INDEX NAME)




RN 342641-57-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl (9CI) (CA INDEX NAME)




RN 342641-59-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-methyl-4-phenyl (9CI) (CA INDEX NAME)




RN 342641-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl (9CI) (CA INDEX NAME)




RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl (9CI) (CA INDEX NAME)




RN 342641-62-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl (9CI) (CA INDEX NAME)




RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl (9CI) (CA INDEX NAME)




RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(1-pyrrolidinyl)ethyl]-2,4-dimethyl (9CI) (CA INDEX NAME)




RN 342641-65-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl (9CI) (CA INDEX NAME)




RN 342641-66-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-67-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-68-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-69-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-70-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-71-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(dimethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-72-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-73-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-74-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-75-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-76-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)



RN 342641-77-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-78-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-79-6 CAPLUS


L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-80-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-81-0 CAPLUS
CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[(4-[(3-diethylamino)propyl]amino)carbonyl]-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-(diethylamino)ethyl)-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-84-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-85-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 342641-88-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxy-5-(1-methylethyl)phenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(3-(1-methylethyl)phenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-95-6 CAPLUS
CN 1H-Indole-6-carboxylic acid,
3-[(4-[(2-(diethylamino)ethyl)amino]carbonyl)-3-(5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-(dimethylamino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-((3-chlorophenyl)amino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-98-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-((3-pyridinylamino)sulfonyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342642-01-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-((dimethylamino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-02-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-((3-chlorophenyl)amino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-08-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342642-10-8 CAPLUS
CN Glycine, N-[(5-((1,2-dihydro-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-11-9 CAPLUS
CN Glycine, N-[(5-((1,2-dihydro-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 342642-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 342642-15-3 CAPLUS




RN 342642-16-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342642-17-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(diethylamino)ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 350668-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356068-90-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-91-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(2-(dimethylamino)ethyl)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-92-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-95-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-96-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-99-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(2)-(5-fluoro-


Double bond geometry as shown.




RN 356069-03-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356069-04-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-05-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356069-07-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356069-09-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-(3,5-dimethyl-1-piperazinyl)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-13-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-(3,5-dimethyl-1-piperazinyl)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-15-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-(3,5-dimethyl-1-piperazinyl)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-24-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylaminio)ethyl]-5-((Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-25-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylaminio)ethyl]-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-26-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylaminio)ethyl]-5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-36-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-(3-(2-oxo-1-pyrrolidinyl)propyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-37-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-(3-(2-oxo-1-imidazolidinyl)ethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-38-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-(3-(2-oxo-1-imidazolidinyl)ethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-39-1 CAPLUS
 CN 1H-Pyrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-40-4 CAPLUS
 CN 1H-Pyrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-41-5 CAPLUS
 CN 1H-Pyrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-42-6 CAPLUS
 CN 1-Piperazineacetic acid, 4-[2-[[5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-43-7 CAPLUS
 CN 1-Piperazineacetic acid, 4-[2-[[5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-44-8 CAPLUS
 CN 1-Piperazineacetic acid, 4-[2-[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-45-9 CAPLUS
 CN 1H-Pyrole-3-carboxamide, N-[2-[(cyanomethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-46-0 CAPLUS
 CN 1H-Pyrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-47-1 CAPLUS
 CN 1H-Pyrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-48-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-49-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-50-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

CRN 76-05-1
CMF C2 H F3 O2




RN 356069-55-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-54-0
CMF C22 H25 N5 O3

Double bond geometry as shown.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 356069-57-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1



RN 356069-51-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylaminio)ethyl]-5-[{(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-53-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-52-8
CMF C22 H24 F N5 O3


Double bond geometry as shown.



CM 2

CRN 356069-56-2
CMF C23 H24 N6 O3

Double bond geometry as shown.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 356069-58-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[2-(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-59-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[2-(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-60-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-61-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-62-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-64-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-63-1
CHM C22 H24 Cl N5 O3

Double bond geometry as shown.




CM 2

CRN 76-05-1
CHM C2 H F3 O2




Double bond geometry as shown.




RN 356069-66-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-77-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[(5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]ethyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




Double bond geometry as shown.



IT 342641-94-5 346405-32-1 356069-16-4


356069-17-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy for treatment of cancer using protein tyrosine kinase inhibitors and cyclooxygenase-2 inhibitors)

RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-


L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
yldiene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX
NAME)



RN 356069-16-4 CAPIUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-
 2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-17-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylxidoamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry as shown.

The chemical structure shows a central amide group (CONH_2) attached to a phenyl ring. The phenyl ring has a $\text{CH}_2\text{CO}_2\text{H}$ group at position 1 and an NHCOCH=CH_2 group at position 2.




RN 356069-14-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-
3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown



RN 468745-41-7 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[{Z}-({5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
 ylidene)methyl]-3,4-dimethyl- (PCI) (CP INDEX NAME)


20 May 1961




IT 342641-53-6* 342642-45-9* 356068-93-4*
[(5'-Fluoro-2-oxo-1,2-dihydroindolin-(3Z)-ylidinemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combination therapy for treatment of cancer using protein tyrosine kinase inhibitor; combination therapy; combination agent)

RN 342641-53-6 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)


L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 IT 342642-09-5 356069-06-2, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 356069-08-4, 5-(2-Oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 356069-10-8,
 5-(2-Oxo-1,2-dihydroindol-3-(2E)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 356069-14-2, 468745-41-7,
 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (combination therapy for treatment of cancer using protein tyrosine kinase inhibitors and cyclooxygenase-2 inhibitors)
 142113-00-0 356069-06-2



RN 356069-06-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidenemethyl)-2,4-dimethyl]- (9CI) (CA INDEX NAME)




RN 356069-08-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-10-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 342642-45-9 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-benzoyl-5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 356068-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(Z)-5-fluoro-1,2-dihydro-2-oxo-3H-indol-


*3-*y*-Indene, methyl-2,4-dimethyl-*



IT 356068-94-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(combination therapy for treatment of cancer using protein tyrosine kinase inhibitors and cyclooxygenase-2 inhibitors)

RN 356068-94-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
 INDEX
 NMRI)

Double bond geometry as shown



ACCESSION NUMBER: 2002-927188 CAPLUS

DOCUMENT NUMBER: 138:14005

TITLE: Preparation of 5-alkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors

INVENTOR(S): Cui, Jingrong; Ramphal, Yudhi; Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 479 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096361	A2	20021205	WO 2002-US16841	20020530
WO 2002096361	A3	20030313		
		W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
		RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG		
US 2003125370	A1	20030703	US 2002-157007	20020530
US 6599902	B2	20030729		
		PRIORITY APPLN. INFO.: US 2001-294544P	P 20010530	
			US 2001-328408P	P 20011010

OTHER SOURCE(S): MARPAT 138:14005
GI

AB: The present invention relates to certain 5-alkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. (shown as I; see below for variable definitions; e.g., 2,4-dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-(3Z)-ylidemethyl)-1H-pyrrole-3-carboxylic acid

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(2-diethylaminoethyl)amide) that inhibit kinases (no data), in particular met kinase. Pharmaceutical compns. comprising these compds., methods of treating diseases mediated by kinases using pharmaceutical compns. comprising these compds., and methods of prep. them are also disclosed. In I: n = 0-2; m = 1-3; R1 and R2 = H or alkyl; R3, R4, and R5 = H, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, alkoxycarbonyl, haloalkoxy, cyano, carboxy, carboxyalkyl, nitro, aryl, aryloxy, heteroaryl, heteroaryloxy, -(alkylene)-CONR10R11, or -NR10R11 (R10 is H or alkyl, and R11 is aryl, heteroaryl, heterocycle, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanocarbonyl, alkoxycarbonylalkyl, heteroaralkyl, aralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy, or R10 and R11 together with the N atom to which they are attached combine to form satd. or unsatd. heterocycloamino). R6 is H, alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, heterocyclylalkyl, aryl, heteroaryl, carboxy, alkoxycarbonyl, heterocyclylcarbonyl, aminoalkylcarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, -(CONR10R11) or -(alkylene)-CONR10R11. R7 and

R8 = H, alkyl, cycloalkyl, heterocyclylalkyl, -COR12, -(alkylene)-COR12 (R12 is alkoxy, hydroxy, or heterocycle, alkylamino, dialkylamino, -SO2R14, -CONR13R14, or -(alkylene)-CONR13R14 (R13 is H or alkyl, and R14 is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanocarbonyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s), or when R13 and R14 are attached to a N atom R13 and

R14 together with the N atom to which they are attached form satd. or unsatd. heterocycloamino). R6 and R7 or R7 and R8 can combine to form a satd. or unsatd. 5 to 8 membered ring; and R9 is: H or alkyl; -PO(OR15)2 where each R15 is H or alkyl; -COR16 where R16 is H or alkyl; or -CH(R17)NR18R19 where R17 is H or alkyl, and R18 and R19 = H or alkyl or

R10 and R11 together with the N atom to which they are attached form heterocycloamino. Although the methods of prep. are not claimed, 375 examples of plus addnl. preps. of intermediates are included. IT 477574-57-5, 2,4-dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidemethyl)-1H-pyrrole-3-carboxylic acid 477574-62-6, 5-(5-(2,6-Dichlorophenyl)methoxy)-2-oxo-1,2-dihydroindol-3-(Z)-ylidemethyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 477574-92-BP, 2-(5-(2,6-Dichlorophenyl)methanesulfonyl)-2-

oxo-1,2-dihydroindol-3-(Z)-ylidemethyl-5-methyl-1H-pyrrole-3-carboxylic acid 477575-20-5P, 5-(5-(2,6-Dimethylphenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 477575-21-6P, 5-(5-(2,3-


Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 477575-91-BP, 5-(5-(3,5-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 477575-93-0P, 5-(5-(2,5-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); and other disorders)

RN 477574-57-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-82-6 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-92-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 5-Methyl-2-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-yldenemethyl)-1H-pyrrole-3-carboxylic acid [3-[1,2,3]triazol-1-ylpropyl]amide 477574-64-4P, 4-Methyl-5-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-yldenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 477574-65-5P, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-yldenemethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide 477574-66-6P, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-yldenemethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide 477574-67-7P, 5-[5-(2-Fluorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide 477574-68-8P, 5-[5-(2-Fluorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 477574-69-9P, 2-[5-(2-

Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide 477574-70-2P, 5-[5-(2-Fluorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diisopropylaminoethyl)amide 477574-71-3P, 2-[5-(2-Fluorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (3-[1,2,3]triazol-1-ylpropyl)amide 477574-74-7P, 5-[5-(2-

Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 477574-75-7P, 2-[5-(3-Chlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (3-[1,2,3]triazol-1-ylpropyl)amide 477574-77-9P, 5-[5-(2-

Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide 477574-78-0P, 5-[5-(3-Chlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-diisopropylaminoethyl)amide 477574-85-9P, 2-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid methyl(1-methylpiperidin-4-yl)amide 477574-88-2P, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(morpholin-4-yl)propyl)amide 477574-89-3P, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(1,2,3-triazol-1-yl)propyl)amide 477574-90-6P, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(3-oxopiperazin-1-yl)ethyl)amide 477574-94-0P, 2-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-(3-oxopiperazin-1-yl)ethyl)amide 477575-11-4P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxyethyl)amide 477575-13-6P, 2-[5-(2,6-

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 yldenemethyl)-1,2-dimethyl-1H-pyrrole-3-carboxylic acid methylamide 477576-07-1P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid amide 477576-09-3P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(4-acetylpirazin-1-yl)ethyl)amide 477576-34-4P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(3-acetylaminopyrrolidin-1-yl)ethyl)amide 477576-45-7P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(2,2,2-trifluoroethylaminoethyl)amide 477576-51-5P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(pyrrolidin-1-yl)propyl)amide 477576-52-6P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-cyclopropylamino-2-hydroxypropyl)amide 477576-55-9P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid cyclopropylamide 477576-57-1P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[4-(2-hydroxyacetyl)piperazin-1-yl]ethyl)amide 477576-58-2P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-cyclopentylamino-2-hydroxypropyl)amide 477576-59-3P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[3-fluoropyrrolidin-1-yl]ethyl)amide 477577-26-7P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[4-(2-amino-2-methylpropionyl)piperazin-1-yl]ethyl)amide 477577-33-6P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[4-(fluoropiperidin-1-yl)ethyl]amide 477577-16-5P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[4-(hydroxypiperidin-1-yl)ethyl]amide 477577-40-5P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-methylpiperidin-4-yl)ethyl)amide 477577-65-4P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid cyclopentyl(R)-1-pyrrolidin-2-ylmethyl)amide 477578-66-5P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (cyclopentylmethyl)(R)-1-pyrrolidin-2-ylmethyl)amide 477577-96-1P, 4-(4-Fluorophenyl)-2-methyl-5-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-yldenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 477578-01-1P, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide 477578-02-2P, 2-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide 477578-03-3P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[3-fluoropiperidin-1-yl]ethyl)amide 477578-04-4P, 2-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(morpholin-4-yl)propyl)amide 477575-15-8P, 2-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(morpholin-4-yl)propyl)amide 477575-16-9P, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid methyl(1-methylpiperidin-4-yl)amide 477575-46-5P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-methoxyethyl)amide 477575-47-6P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-methoxypropyl)amide 477575-48-7P, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(2-hydroxyethyl)ethyl)amide 477575-49-8P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(2-hydroxyethyl)ethyl)amide 477575-50-1P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-1-bis(hydroxyethyl)ethyl)amide 477575-57-8P, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(morpholin-4-yl)ethyl)amide 477575-58-9P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-morpholin-4-yl)amide 477575-64-7P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylsulfanyethyl)amide 477575-65-8P, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(2-trifluoroethyl)ethyl)amide 477575-86-3P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-4-yl)ethyl)amide 477575-89-6P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-3-yl)ethyl)amide 477575-90-8P, 5-[5-(2,6-


Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(tetrahydrofuran-2-yl)methyl)amide 477575-92-1P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (cyclopropylmethyl)amide 477576-04-8P, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-fluoroethyl)amide 477576-09-9P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-4-yl)ethyl)amide 477576-06-0P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)]-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-3-yl)ethyl)amide 477576-04-8P, 5-[5-(2,6-

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepns. of aralkylsulfonyl- and pyrrolylmethylenesubstituted indolinones as kinase inhibitors useful against cancers and other disorders)


RN 477573-60-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylaminoethyl)-5-[(Z)-1,2-dihydro-2-oxo-5-[phenylmethyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-61-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-5-[(2-cyanophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylaminoethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-62-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylaminoethyl)-5-[(Z)-1,2-dihydro-2-oxo-5-[(3-trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-63-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylaminoethyl)-5-[(2)-(1,2-dihydro-5-[(3-methoxyphenyl)methyl]sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-67-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylaminoethyl)-5-[(2)-(1,2-dihydro-5-[(2-nitrophenyl)methyl]sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-68-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-75-4 CAPLUS
CN Benzenoacetic acid,
4-[(1S)-3-[(4-[(2-(diethylamino)ethyl]amino)carbonyl]-5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-ylsulfonyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




PAGE 1-A
PAGE 1-B

-NET₂


RN 477573-76-5 CAPLUS
CN Benzoic acid,
4-[(1S)-3-[(4-[(2-(diethylamino)ethyl]amino)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-ylsulfonyl)methyl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-69-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(1,2-dihydro-5-[(2-nitrophenyl)methyl]sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-74-3 CAPLUS
CN Benzoic acid,
4-[(1S)-3-[(4-[(2-(diethylamino)ethyl]amino)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-ylsulfonyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-78-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-[(3,5-dibromo-2-hydroxyphenyl)methyl]sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-79-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-(5-[(2-fluorophenyl)methyl]sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 477573-80-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-4-methyl-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-81-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-82-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-83-4 CAPLUS
CN Benzoic acid,
4-[[((Z)-3-[[4-[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
y1sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylaminoethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-88-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(4-bromophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-89-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[(2-iodophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-91-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(4-cyanophenyl)methyl]sulfonyl]-1,2-

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-y1sulfonyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




PAGE 1-A

PAGE 1-B

-NEt2

RN 477573-84-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(4-(trifluoromethoxy)phenyl)methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-A


PAGE 1-B

-NEt2

RN 477573-86-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[2,4-bis(trifluoromethyl)phenyl]meth-

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-A

PAGE 1-B

-NEt2

RN 477573-93-6 CAPLUS
CN Benzoic acid,
3-[[((Z)-3-[[4-((2-(diethylamino)ethyl)amino)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-y1sulfonyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


PAGE 1-A

PAGE 1-B

Double bond geometry as shown.

RN 477573-96-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(3-(trifluoromethoxy)phenyl)methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




PAGE 1-B

—NET₂

RN 477573-98-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-5-((3-cyanophenyl)methyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-00-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylaminoethyl)-5-[(Z)-(1,2-dihydro-5-((3-methylphenyl)methyl)sulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-04-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-5-((4-(1,1-dimethylethyl)phenyl)methyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-06-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-5-((2,6-difluorophenyl)methyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-08-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-5-((3-chlorophenyl)methyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-11-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylaminoethyl)-5-[(Z)-(1,2-dihydro-5-((4-nitrophenyl)methyl)sulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-13-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylaminoethyl)-5-[(Z)-(1,2-dihydro-5-((3-nitrophenyl)methyl)sulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-14-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-5-((3-bromophenyl)methyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-16-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-5-((3,5-difluorophenyl)methyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-18-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-5-((3,4-difluorophenyl)methyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-20-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
S-[(Z)-5-[[2,5-bis(trifluoromethyl)phenyl]methoxy]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-22-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
S-[(Z)-5-[[3,5-bis(trifluoromethyl)phenyl]methoxy]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-24-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[(2-hydroxy-5-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-26-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[(2-methoxy-5-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-28-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-30-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(3-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-32-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(4-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-35-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-3-[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-37-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[4-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-40-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[pentafluorophenyl]methyl]sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-42-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(2,5-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-44-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{1,2-dihydro-2-oxo-5-[(2,3,6-trifluorophenyl)methylsulfonyl]-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-46-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{5-[(2,3-difluorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-47-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{5-[(2,6-dichlorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{5-[(2-(2-fluorophenoxy)phenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-55-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{5-[(4-chlorophenoxy)phenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-59-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-{1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-60-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-49-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{5-[(1,1'-biphenyl)-2-ylmethyl}sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-51-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{5-[(2-fluoro-6-nitrophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-53-1 CAPLUS


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-61-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-62-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-{1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene}methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-64-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-65-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-66-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-[bis(1-methylethyl)amino]ethyl]-5-[(Z)-[1,2-


RN 477574-69-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-5-[(2-fluorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-70-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[(Z)-[5-[(2-fluorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-71-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-[5-[(2-fluorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1H-1,2,3-triazol-1-ylpropyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

Double bond geometry as shown.





RN 477574-67-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2-fluorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-68-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2-fluorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-74-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(3-chlorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-75-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-[5-[(3-chlorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-76-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-[5-[(3-chlorophenyl)methylsulfonyl]-1,2-


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-methyl-N-(3-(1H-1,2,3-triazol-1-yl)propyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-77-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(z)-{5-[(3-chlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-78-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(bis(1-methylethyl)amino)ethyl]-5-[(z)-{5-[(3-chlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 477574-89-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-90-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

-N(Pr-i)2

RN 477574-85-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N,5-dimethyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-88-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 477574-94-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-11-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-hydroxyethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-13-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-15-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-
morpholinyl)propyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-16-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-N-(1-methyl-4-
piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(2-hydroxyethoxy)ethyl]-
2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




PAGE 1-A

PAGE 1-B

-OH


RN 477575-49-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-1-
(hydroxymethyl)-1-methylethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-50-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-1,1-
bis(hydroxymethyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-46-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-methoxyethyl)-2,4-
dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-47-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(3-methoxypropyl)-2,4-
dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-48-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-




RN 477575-57-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-
morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-58-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(3-(4-
morpholinyl)propyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-64-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(ethylthio)ethyl]-2,4-
 dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-65-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2,2,2-
 trifluoroethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-86-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-
 pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-89-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-
 pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-90-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-
 pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-91-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(tetrahydro-2-
 furanyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-92-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-(cyclopropylmethyl)-S-[(Z)-[5-[(2,6-
 dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
 ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-04-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-fluoroethyl)-2,4-
 dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-05-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-
 yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-06-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 S-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl- (9CI) (CA
 INDEX NAME)

Double bond geometry as shown.




L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
RN 47756-07-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
S-[(2-[5-((2,6-dichlorophenyl)methyl)sulfonyl]-
2,1-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.



RN 477576-09-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-acetyl-1-piperazinyl)ethyl]-5-[(Z)-5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-34-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3-(acetylamino)-1-pyrrolidinyl)ethyl]-5-
{[(Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-1,2-dihydro-2-oxo-3H-indol-
3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 477576-45-7 CAPLUS
 CN 1H-Pyrido[3,2-d]imidazole-3-carboxamide,
 5-[{Z}-5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-((2,2,2-
 trifluoroethyl)amino)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-51-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[{ α -(5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1-pyrrrolidinyl)propyl]-2,4-dimethyl (α C1) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-52-6 CAPLUS


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 N-13-(cyclopropylamino)-2-hydroxypropyl]-5-[(Z)-
 {5-[(2,6-dichlorophenyl)methyl]phenyl}-1,2-dihydro-2-oxo-3H-indol-3-
 ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-55-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 47756-57-1 CAPLUS
CN 1H-Pyrrole-3-carboamide,
CN-[(2)-{5-[{[2,6-dichlorophenyl]methyl} sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl}-N-[2-[4-(hydroxyacetyl)-1-
piperazinyl]ethyl]ethyl-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



PAGE 1-B

RN 477576-95-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-(2-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(4-fluoro-1-
 piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-16-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-(3-fluoro-1-pyridinyl)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-26-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-{4-(2-amino-2-methyl-1-oxopropyl)-1-piperazinyl}ethyl]-5-[(Z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-A


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

-NH₂


RN 477577-33-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(4-hydroxy-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-40-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-65-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-5-[(Z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ylidene)methyl]-2,4-dimethyl-N-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 477577-66-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-(cyclopropylmethyl)-5-[(Z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 477577-96-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylaminoethyl)-5-[(Z)-{1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene)methyl]-4-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 477578-01-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(3-(1-pyrrolidinyl)propyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477578-02-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[(3-(1-pyrrolidinyl)propyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477578-03-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-{5-[(2,6-dichlorophenyl)methyl]sulfonyl}-


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3-fluoro-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477578-04-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 477577-22-3, 5-(5-(2,6-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aralkylsulfonyl- and pyrrolylmethylenesubstituted indolinones as kinase inhibitors useful against cancers and other disorders)
 RN 477577-22-3 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-[(2,6-difluorophenyl)methyl]sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

—OBu-t

RN 477576-59-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-60-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-[(4-(acetoxy)acetyl)-1-piperazinyl]ethyl]-5-[(Z)-5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 477576-58-2P, 4-[(5-[(5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrol-3-ylcarbonyl]amino)ethyl]piperazine-1-carboxylic acid tert-butyl ester
 477576-59-3P, 5-(5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(piperazin-1-yl)ethyl)amide 477576-60-6P, Acetic acid
 2-[4-[(5-[(5-(2,6-dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrol-3-ylcarbonyl]amino)ethyl]piperazin-1-yl]-2-oxoethyl ester
 477577-27-8P, [2-[(2-[(5-[(5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-yldenemethyl)-2,4-dimethyl-1H-pyrrol-3-ylcarbonyl]amino)ethyl]piperazin-1-yl]-1,1-dimethyl-2-oxoethyl]carbamic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aralkylsulfonyl- and pyrrolylmethylenesubstituted indolinones as kinase inhibitors useful against cancers and other disorders)

RN 477576-58-2 CAPLUS
 CN 1H-Piperazinecarboxylic acid, 4-[(2-[(5-[(2,6-dichlorophenyl)methyl]sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonylamino)ethyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.

PAGE 1-A



L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—OAc


RN 477577-27-8 CAPLUS
 CN Carbamic acid,
 [2-[(2-[(5-[(2,6-dichlorophenyl)methyl]sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino)ethyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



ACCESSION NUMBER: 2002:793619 CAPLUS

DOCUMENT NUMBER: 137:294870

TITLE: Preparation of prodrugs of

3-(pyrrol-2-ylmethylidene)-

2-indolinones and activity as modulators of protein

kinases

INVENTOR(S): Sun, Connie Li; Wei, Chung Chen; Tang, Peng Cho;

Koenig, Marcel; Zhou, Yong; Vojkovsky, Tomas;

Nematalia, Asaad S.

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: PCT Int. Appl., 194 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081466	A1	20021017	WO 2002-US11001	20020409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, HI, MR, NE, SN, TD, TG				
US 2003100555	A1	20030529	US 2002-118321	20020409
US 6797725	B2	20040928		
US 2004186161	A1	20040923	US 2004-816957	20040405
PRIORITY APPLN. INFO.:			US 2001-282630P	P 20010409
			US 2002-118321	A3 20020409

OTHER SOURCE(S): MARPAT 137:294870
GI

AB The present invention relates to pyrrole substituted 2-indolinone compds. (shown as I; e.g. 3-[1-(3,5-dimethyl-1H-pyrrol-2-yl)meth-(2)-ylidene]-2-oxo-2,3-dihydroindole-1-carbonyl chloride) and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer (no data). In I,

R1 and R2 are independently H, halo, alky, alkylthio, nitro, trihalomethyl, hydroxy, hydroxylalkyl, alkoxy, cyano, aryl, heteroaryl, -C(O)R7 (R7 is alky, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, heterocycle, and aminoalkylamino), -NR8R9, -NR8C(O)R9, -SO2R8, and -S(O)2NR8R9 (R8 and R9 are independently H, alky, aryl and heteroaryl, or R8 and R9 together with the N to which they are attached form a satd. heterocycloamino). R3 is H, alky, hydroxylalkyl, -C(O)R7, aryl, and heteroaryl; R4 is H, alky, -C(O)R7 aryl, and heteroaryl. R5 is H and -COR10 where R10 is alky, alkoxy, hydroxy, aryl, aryloxy, heteroaryl, heterocycle, alkylamino, dialkylamino, or -NR11R12 where R11 is H or alky, and R12 is aminoalkyl, hydroxylalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxy carbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alky chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s); or R4 and R5 together form - (CH2)4- or -(CH2)nO(CH2)n- wherein n is 0 to 3, provided that n+m is 3. R6 is: (c) -OR13 wherein R13 is alky, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonoalkyl, sulfoxyalkyl, hydroxylalkyl, aryloxyalkyl, aryl, heteroaryl, heteroaralkyl, heterocycle, monosaccharides and heterocyclylalkyl wherein the alky chain in carboxyalkyl, aminoalkyl, phosphonoalkyl, sulfoxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxylalkyl, or aryloxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in said alky chain are optionally replaced by O, (R14- (R14 is H or alky), -S-, or -SO2-; or (d) -NR15R16 where R15 and R16 are independently H, alky, carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonoalkyl, sulfoxyalkyl, hydroxylalkyl, aryl, heteroaralkyl, heterocyclylalkyl, and heterocyclylalkyl; Wherein the alky chain in carboxyalkyl, aminoalkyl, phosphonoalkyl, heteroaralkyl, heterocyclylalkyl, hydroxylalkyl, or aryloxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in the alky chain are optionally replaced by O, (R17- (R17 is H or alky), -S-, or -SO2-; or R15 and R16 together with the N atom to which they are attached form satd. or unsatd. heterocycloamino. Although the methods of prepns. are not claimed, >80 example prepns. are included, both of I and the unprotected version of I in which the C(O)R6 group has been replaced by H.

IT 356068-93-4P, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3(2)-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
356068-94-5P, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3(2)-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of prodrugs of

(pyrrolidinylmethylidene)indolinones


and activity as modulators of protein kinases)

RN 356068-93-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid,


S-[{(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3(2)-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




IT 356069-06-2, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 356069-08-4, 5-(2-Oxo-1,2-dihydroindol-3-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 356069-10-8, 5-(2-Oxo-1,2-dihydroindol-3(2)-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 356069-14-2, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3(2)-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 468745-41-7, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3(2)-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 468745-44-0, 5-(5-Cyano-2-oxo-1,2-dihydroindol-3(2)-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of prodrugs of (pyrrolidinylmethylidene)indolinones and activity as modulators of protein kinases)

RN 356069-06-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3(2)-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Continued)




RN 356069-08-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-10-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[{2}-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-14-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(Z)-5-chloro-1,2-dihydro-2-oxo-3H-indol-
3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 468745-41-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-((2-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Continued)




1H-pyrazole-2-carboxylic acid 326241-17-2P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-4-methyl-1H-pyrrole-2-carboxylic acid 326241-05-0P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-4-isopropyl-1-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide 342641-50-3P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide 342641-51-4P,
 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342641-52-5P
 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid [3-(4-methylpiperazin-1-yl)propyl]amide 342641-54-7P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide 342641-55-8P, 5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidene]ethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide 342641-56-9P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide 342641-57-0P
 5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidene]ethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide 342641-59-2P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide 342641-60-5P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide 342641-61-6P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2,4-dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidene)ethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide 342641-62-7P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide 342641-63-8P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342641-64-9P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide 342641-65-0P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl)amide 342641-66-1P, 5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidene]ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide 342641-67-2P, 5-[6-(3-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidene]ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide 342641-68-3P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidene)ethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342641-69-4P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidene)ethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide 342641-70-7P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)ethyl)-2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidene)ethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide 342641-71-8P




RN 468745-44-0 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[{Z}-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-
 ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 342641-53-6P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid 557795-19-4P; 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3(2Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THF (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase modulator; preparation of prodrugs of (pyrrolylmethylidene)indolinones and activity as modulators of protein kinases)
 PW 342641-53-6 CAPTUS

RN 342614-53-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

(3-(imidazol-1-yl)propyl)amide



5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-03-29**,
 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-disopropyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-84-39**,
 , 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-disopropyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-85-49**,
 , 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-disopropyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl)propyl)amide
342641-87-69, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
 2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)amide
342641-88-79, 5-(6-(4-Butylphenyl)-2-oxo-1,2-dihydroindol-3-
 ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid

5-[6-(5-Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-
 2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
 342641-91-2P, 5-[6-(4-Ethylphenyl)-2-oxo-1,2-dihydroindol-3-
 ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 (2-(pyrrolidin-1-yl)ethyl)amide 342641-92-3P,
 5-[6-(2,4-Dimethoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-
 dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
 342641-93-4P, 5-[6-(3-Isopropophenyl)-2-oxo-1,2-dihydroindol-3-
 ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 (2-(pyrrolidin-1-yl)ethyl)amide 342641-94-5P,
 5-[5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-
 pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342641-95-6P
 , 3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-2-pyrrol-2-
 ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid
 342641-96-7P, 5-[5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-
 ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 (2-(pyrrolidin-1-yl)ethyl)amide 342641-97-8P,

L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(pyrrolidin-1-yl)ethyl]amide 342641-98-97, 2,4-Dimethyl-5-[2-(pyridin-3-sulfamoyl)-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [2-(pyrrolidin-1-yl)ethyl]amide 342642-01-79, 5-[5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(diethylaminoethyl)ethyl]amide 342642-02-89, 5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [2-(diethylaminoethyl)ethyl]amide 342642-08-49, 4-Methyl-5-[5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid 342642-09-59, [(4-Methyl-5-(4-methyl-5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid]amino[acetic acid ethyl ester 342642-10-89,

[(4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid]amino[acetic acid ethyl ester 342642-11-99,

[(4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid]amino[acetic acid ethyl ester 342642-12-09,

5-Methyl-2-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid 342642-15-39, 2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 342642-17-59, 2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid [2-(diethylaminoethyl)ethyl]amide 346405-32-19, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-3-carboxylic acid [2-(pyrrolidin-1-yl)ethyl]amide 356068-82-19, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-3-carboxylic acid [2-(pyrrolidin-1-yl)ethyl]amide 356068-90-19, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(diethylaminoethyl)ethyl]amide 356068-91-29, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid [2-(diethylaminoethyl)ethyl]amide 356068-92-39, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid [2-(pyrrolidin-1-ethyl)ethyl]amide 356068-95-69, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid [2-(dimethylaminoethyl)ethyl]amide 356068-96-79, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(dimethylaminoethyl)ethyl]amide 356068-97-89, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(ethylaminoethyl)ethyl]amide 356068-99-09, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(diethylaminoethyl)ethyl]amide 356069-03-99,


acid (2-diethyl-N-oxoaminooethyl)amide 356069-03-99,

5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide 356069-04-09, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide 356069-05-19, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide 356069-07-39, 5-(2-Oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide 356069-09-59, 5-(2-Oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide 356069-12-09, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide 356069-13-19,


L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide 356069-15-39, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide 356069-16-40, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide 356069-17-40, [(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (protein kinase modulator; prepn. of prodrugs of (pyrrolylmethylidene)indolinones and activity as modulators of protein kinases)]


RN 280748-39-2 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 342641-17-2 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(5-chloro-2-oxo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-49-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(3-(diethylamino)propyl)-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-50-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-(1-methylethyl)-4-phenyl-

L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

5-((5-bromo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-(diethylamino)ethyl)-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-51-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-(diethylamino)ethyl)-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-52-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl- (9CI) (CA INDEX NAME)


L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 342641-54-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-55-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-56-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-57-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-59-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-phenyl-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-62-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-65-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-66-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-67-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-68-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-69-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-70-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-(3-(1H-imidazol-1-yl)propyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-71-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-72-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-73-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-(3-(1H-imidazol-1-yl)propyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-74-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-75-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-76-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-77-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-78-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-79-6 CAPLUS




RN 342641-80-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-81-0 CAPLUS
CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[(4-[(3-dimethylamino)propyl]amino)carbonyl]-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-84-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-85-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 342641-88-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[{5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-95-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-{[4-[(2-(diethylamino)ethyl)amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene}-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{5-(dimethylamino)sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{5-((3-chlorophenyl)amino)sulfonyl}-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-98-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[{1,2-dihydro-2-oxo-5-((3-pyridylamino)sulfonyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342642-01-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-(dimethylamino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-02-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-[(3-chlorophenyl)amino]sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-08-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342642-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 342642-15-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 342642-17-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX




RN 342642-09-5 CAPLUS
CN Glycine, N-[(5-[(1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-10-8 CAPLUS
CN Glycine, N-[(5-[(1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-11-9 CAPLUS
CN Glycine, N-[(5-[(1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 356068-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356068-90-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-91-2 CAPLUS
CN 1H-Pyrrrole-3-carboxamide,
N-[2-(diethylaminoethyl)-5-[(1,2-dihydro-2-oxo-
3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-92-3 CAPLUS
CN 1H-Pyrrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-95-6 CAPLUS
CN 1H-Pyrrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-96-7 CAPLUS
CN 1H-Pyrrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-
dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX
NAME)



RN 356068-97-8 CAPLUS
CN 1H-Pyrrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(2)-(5-fluoro-1,2-
dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.




RN 356068-99-0 CAPLUS
CN 1H-Pyrrrole-3-carboxamide,
N-[2-(diethyloxidoamino)ethyl]-5-[(2)-(5-fluoro-
1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.




RN 356069-03-9 CAPLUS
CN 1H-Pyrrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 356069-04-0 CAPLUS
CN 1H-Pyrrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 356069-05-1 CAPLUS
CN 1H-Pyrrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 356069-07-3 CAPLUS
CN 1H-Pyrrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356069-09-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-13-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-15-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 468745-38-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-pyridinyl)ethyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002-658111 CAPLUS
DOCUMENT NUMBER: 137:185408
TITLE: 3-(4-Aminopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors

INVENTOR(S): Guan, Huiping; Liang, Congxin; Sun, Li; Tang, Peng Cho; Wei, Chung Chen; Mauragis, Michael A.; Vojkovsky,

PATENT ASSIGNEE(S): Tomas; Jin, Qingwu; Herrinton, Paul Matthew

SOURCE: USA PCT Int. Appl., 167 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066463	A1	20020829	WO 2002-US4407	20020215
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OH, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, HL, MR, NE, SN, TD, TG	CA 2438314	AA 20020829	CA 2002-2438314
CA 2438314	AA	20020829	CA 2002-2438314	20020215
US 2003092917	A1	20030515	US 2002-76140	20020215
US 6653308	B2	20031125		
EP 1370554	A1	20031217	EP 2002-714897	20020215
EP 1370554	B1	20051019		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	EE 200300385	A	20040216	EE 2003-385
EE 200300385	A	20040216	EE 2003-385	20020215
BR 2002007494	A	20040427	BR 2002-7494	20020215
JP 2004522776	T2	20040729	JP 2002-565978	20020215
JP 3677501	B2	20050803		
CN 1529704	A	20040915	CN 2002-806680	20020215
NZ 527572	A	20050729	NZ 2002-527572	20020215
CA 2475455	AA	20030828	CA 2003-2475455	20030214
WO 2003070725	A2	20030828	WO 2003-US4520	20030214
WO 2003070725	A3	20040115		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OH, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, HL, MR, NE, SN, TD, TG	US 200329229	A1	20031211
US 200329229	A1	20031211	US 2003-367000	20030214
EP 1476443	A2	20041117	EP 2003-742760	20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	BR 2003007721	A	20050125	BR 2003-7721
BR 2003007721	A	20050125	BR 2003-7721	20030214
JP 2005526344	T2	20050922	JP 2003-569632	20030214

L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 NO 2003003608 A 20031014 NO 2003-3608 20030814
 ZA 2003006335 A 20041115 ZA 2003-6335 20030814
 US 2004102510 A1 20040527 US 2003-656907 20030908
 ZA 2004005615 A 20050627 ZA 2004-5615 20040714
 US 2005171357 A1 20050804 US 2005-95433 20050330
 PRIORITY APPLN. INFO.:
 US 2001-268683P P 20010215
 US 2001-312361P P 20010815
 US 2002-76140 A3 20020215
 WO 2002-US4407 W 20020215
 US 2002-411732P P 20020918
 US 2003-367008 A3 20030214
 WO 2003-US4520 W 20030214

OTHER SOURCE(S): MARPAT 137:185408
 GI



I




II


AB Title compds. I [R1 = H, halo, alkyl, haloalkoxy, cycloalkyl, heterocyclic, OH, alkoxy, (un)esterified CO₂H, (un)substituted NH₂, CONH₂; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (un)substituted NH₂, SO₂NH₂, (un)esterified CO₂H, SO₂R₈, R8 = alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; R3-R6 = H, alkyl; R7 = H, alkyl, aryl, heteroaryl, acyl; Z = aryl, heteroaryl, heterocyclic, (un)substituted NH₂] were prepared for use

L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 as protein kinase inhibitors in treatment of diseases, such as cancer (no data). Thus, Et 3,5-dimethyl-4-pyrrolecarboxylate was oxidized to the 5-fluoro-2-oxindole, followed by ester hydrolysis, reaction with R1: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivs. as protein kinase inhibitors)
 RN 356068-93-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-((2-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-06-2 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-08-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-14-2 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-((2-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 452105-39-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452105-65-6 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-((2)-(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 452105-33-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivs. as protein kinase inhibitors)

RN 452105-33-8 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)



L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 375798-55-3P 452104-42-6P 452104-43-7P

452104-44-8P 452104-45-9P 452104-46-0P

452104-47-1P 452104-48-2P 452104-49-3P

452104-50-6P 452104-51-7P 452104-52-8P

452104-53-9P 452104-54-0P 452104-55-1P

452104-56-2P 452104-57-3P 452104-59-4P

452104-59-5P 452104-60-8P 452104-61-9P

452104-62-0P 452104-63-1P 452104-64-2P

452104-65-3P 452104-66-4P 452104-67-5P

452104-69-6P 452104-69-7P 452104-70-0P

452104-71-1P 452104-72-2P 452104-73-3P

452104-74-4P 452104-75-5P 452104-76-6P

452104-77-7P 452104-78-8P 452104-79-9P

452104-80-2P 452104-81-3P 452104-82-4P

452104-83-5P 452104-84-6P 452104-85-7P

452104-86-8P 452104-87-9P 452104-89-0P

452104-90-1P 452104-90-4P 452104-91-5P

452104-92-6P 452104-93-7P 452104-94-8P

452104-95-9P 452104-96-0P 452104-97-1P

452104-98-2P 452104-99-3P 452105-00-9P

452105-01-0P 452105-02-1P 452105-03-2P

452105-04-3P 452105-05-4P 452105-06-5P

452105-07-6P 452105-08-7P 452105-09-8P

452105-10-1P 452105-11-2P 452105-12-3P

452105-13-4P 452105-14-5P 452105-15-6P

452105-16-7P 452105-17-8P 452105-18-9P

452105-19-0P 452105-20-1P 452105-21-2P

452105-22-5P 452105-23-6P 452105-24-7P

452105-25-8P 452105-26-9P 452105-27-0P

452105-28-1P 452105-29-2P 452105-30-5P

452105-31-6P 452105-32-7P 452105-44-1P

452105-45-2P 452105-46-3P 452105-47-4P

452105-62-3P 452105-63-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivs. as protein kinase inhibitors)


RN 375798-55-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 452104-42-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-43-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)




RN 452104-44-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-45-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)




RN 452104-46-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)




RN 452104-47-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-48-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-49-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-50-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-51-7 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl]amino)carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)




RN 452104-52-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl]amino)carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
hydroxymethyl-2,3-dihydro-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)




RN 452104-57-3 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl]amino)carbonyl]-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 452104-58-4 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(3-(4-cyanophenyl)-4-[(3-(diethylamino)-2-hydroxypropyl]amino)carbonyl]-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 452104-59-5 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl]amino)carbonyl]-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 452104-54-0 CAPLUS
CN 1H-Pyrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene)methyl]-4-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 452104-55-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl]amino)carbonyl]-3-(4-fluorophenyl)-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 452104-56-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-


RN 452104-59-5 CAPLUS
CN 1H-Pyrole-3-carboxamide, 4-(4-cyanophenyl)-N-[3-(diethylamino)-2-hydroxypropyl]-5-[(1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 452104-60-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(3-(4-chlorophenyl)-4-[(3-(diethylamino)-2-hydroxypropyl]amino)carbonyl]-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 452104-61-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(3-(4-chlorophenyl)-4-[(3-(diethylamino)-2-hydroxypropyl]amino)carbonyl]-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 452104-62-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-63-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-64-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-65-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-66-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-67-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-68-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-69-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-70-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-71-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-72-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-73-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-74-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
S-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-
N-(3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl)-2,4-dimethyl- (9CI)
(CA INDEX NAME)



RN 452104-75-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-S-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-76-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-77-7 CAPLUS

L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Pyrrole-3-carboxamide, 5-[{5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-78-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[{5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)




L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 452104-79-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[{5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 2-A


L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




L12 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A



RN 452104-81-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[{1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




PAGE 2-A




RN 452104-82-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[{5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-A



PAGE 2-A




PAGE 2-A




RN 452104-83-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-((3-oxido-1H-benzotriazol-1-yl)oxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-84-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-((3-oxido-1H-benzotriazol-1-yl)oxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 452104-85-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-86-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-

Double bond geometry as shown.




RN 452104-87-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-88-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-89-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-90-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-, (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-91-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-, (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-92-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-, (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-96-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(3-(diethylamino)-2-hydroxypropyl)-5-[(Z)-[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(4-fluorophenyl)-2-methyl-1H-pyrrol-2-yl]methyl-, (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-97-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl)amino]carbonyl)-3-(4-fluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylen]-2,3-dihydro-N-(1-methylethyl)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-98-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl)amino]carbonyl)-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-




RN 452104-93-7 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl)amino]carbonyl)-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylen]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-94-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl)amino]carbonyl)-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylen]-2,3-dihydro-N-methyl-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-95-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl)amino]carbonyl)-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylen]-2,3-dihydro-2-oxo-N-(2-hydroxyethyl)-1H-pyrrol-2-yl group is attached to the indole ring at position 5.

Double bond geometry as shown.


y1)methylene]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-99-3 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-[(3-(diethylamino)-2-hydroxypropyl)amino]carbonyl)-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylen]-2,3-dihydro-N-(2-hydroxyethyl)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-00-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(3-(4-cyanophenyl)-4-[(3-(diethylamino)-2-hydroxypropyl)amino]carbonyl)-5-methyl-1H-pyrrol-2-yl]methylen]-2,3-dihydro-N,N-dimethyl-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-01-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(4-cyanophenyl)-N-[3-(diethylamino)-2-hydroxypropyl]-5-{(Z)-[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl}-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-02-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(3-(4-chlorophenyl)-4-[[{3-(diethylamino)-2-hydroxypropyl}amino]carbonyl]-5-methyl-1H-pyrrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-03-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(3-(4-chlorophenyl)-4-[[{3-(diethylamino)-2-hydroxypropyl}amino]carbonyl]-5-methyl-1H-pyrrrol-2-yl)methylene]-2,3-

Double bond geometry as shown.




RN 452105-04-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-05-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-{(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-06-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-{(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl}-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-07-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-08-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-{(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-09-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-{(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl}-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-10-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-((2R,6S)-2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-5-{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452105-11-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-{(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[3-((2R,6S)-2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452105-12-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-{(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl}-N-[3-((2R,6S)-2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452105-13-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-14-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-15-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-19-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-20-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl)-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-21-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-16-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-17-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-18-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-22-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-25-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-26-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-27-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-28-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 452105-29-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[(2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 452105-30-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2-hydroxy-3-(3-oxido-1H-benzotriazol-1-yl)oxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-31-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2-hydroxy-3-(3-oxido-1H-benzotriazol-1-yl)oxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 452105-32-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[(2-hydroxy-3-(3-oxido-1H-benzotriazol-1-yl)oxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 452105-44-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-45-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2-hydroxy-3-(3-oxido-1H-benzotriazol-1-yl)oxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-46-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-47-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-62-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-63-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ACCESSION NUMBER: 2002-539677 CAPLUS
DOCUMENT NUMBER: 137:109202
TITLE: Preparation of 4-aryl substituted indolinones as protein kinase signal transduction modulators for inhibiting abnormal cell proliferation
INVENTOR(S): Cui, Jingzong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu; Zhang, Fang-Jie; Koenig, Marcel; Do, Steven Huy; Li, Xiaoyuan; Wei, Chung Chen; Tang, Peng Cho
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 560 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055517	A2	20020718	WO 2001-US40564	20011220
WO 2002055517	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GU, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MM, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, ZY				
TJ, TH				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CN, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2432114	AA	20020718	CA 2001-2432114	20011220
US 2003069297	A1	20030410	US 2001-23488	20011220
US 6677368	B2	20040113		
EP 1349852	A2	20031008	EP 2001-997065	20011220
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518669	T2	20040624	JP 2002-556186	20011220
US 2004157909	A1	20040812	US 2003-736243	20031216
US 6661418	B2	20050301		
PRIORITY APPLN. INFO.:			US 2000-256479P	P 20001220
			US 2001-23488	A3 20011220
			WO 2001-US40564	W 20011220

OTHER SOURCE(S): MARPAT 137:109202
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = (un)substituted aryl or heteroaryl; R2 = H, halo, alkyl, alkenyl, alkynyl, heterocycl, etc.; R3 = (un)substituted pyrrole or cycloalkenylpyrrole], as well as pharmaceutical compds. thereof, are prepared and disclosed as compds. capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Thus II, was prepared via condensation of

L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
4-phenyl-1,3-dihydroindol-2-one with 5-formyl-2-methyl-4-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxylic acid Et ester. I were evaluated against eight specific kinases, e.g., FGFR1, for which I possessed IC50 values (μ M) of 0.0091-2.07. The present invention also related to methods for treating protein kinase related disorders.

IT 442563-63-5
RL (Reactant); RACT (Reactant or reagent)
(preparation of (aryl)(pyrrolymethylene)indolinones as protein kinase signal transduction modulators)
RN 442563-63-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(Z)-4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 442558-05-6P 442558-07-8P 442558-08-9P
442558-09-0P 442558-11-4P 442558-15-8P
442558-16-9P 442558-17-0P 442558-23-0P
442558-24-9P 442558-25-0P 442558-31-0P
442558-32-0P 442558-33-0P 442558-36-3P
442558-39-6P 442558-40-9P 442558-41-0P
442558-43-2P 442558-44-3P 442558-46-7P
442558-49-0P 442558-50-1P 442558-52-3P
442558-53-4P 442558-54-5P 442558-56-7P
442558-57-1P 442558-58-9P 442558-60-3P
442558-61-4P 442558-62-5P 442558-63-6P
442558-65-0P 442558-66-9P 442558-67-0P
442558-69-2P 442558-70-5P 442558-71-6P
442558-72-7P 442558-73-8P 442558-74-9P
442558-75-0P 442558-76-1P 442558-77-2P
442558-78-3P 442558-79-4P 442558-80-5P
442558-89-6P 442558-90-0P 442558-91-0P
442558-92-1P 442558-93-2P 442558-94-3P
442558-96-5P 442558-97-6P 442558-98-7P
442558-99-0P 442558-04-0P 442558-05-9P
442558-03-7P 442558-04-0P 442558-05-9P
442558-07-1P 442558-08-2P 442558-09-3P
442558-10-6P 442558-11-7P 442558-12-8P
442558-14-0P 442558-15-1P 442558-19-5P
442558-20-0P 442558-21-0P 442558-22-0P
442558-23-1P 442558-42-4P 442558-43-5P
442558-44-5P 442558-45-7P 442558-46-8P
442558-53-7P 442558-54-8P 442558-55-9P
442558-57-1P 442558-58-2P 442558-59-3P
442558-60-6P 442558-79-7P 442558-80-0P


442559-01-1P 442559-94-6P 442559-97-9P
 442559-98-0P 442559-99-1P 442560-00-1P
 442560-01-2P 442560-02-3P 442560-03-4P
 442560-04-5P 442560-12-9P 442560-17-0P
 442560-31-8P 442560-39-6P 442560-43-2P
 442560-44-3P 442560-45-4P 442560-46-5P
 442560-47-6P 442560-48-7P 442560-49-8P
 442560-51-2P 442560-52-3P 442560-59-0P
 442560-64-7P 442560-65-8P 442560-66-9P
 442560-69-2P 442560-79-4P 442560-80-7P
 442560-81-8P 442560-83-0P 442560-88-5P
 442560-89-6P 442561-01-5P 442561-02-6P
 442561-04-8P 442561-05-9P 442561-06-0P
 442561-07-1P 442561-08-2P 442561-09-3P
 442561-10-6P 442561-11-7P 442561-12-8P
 442561-13-9P 442561-29-7P 442561-31-1P
 442561-32-2P 442561-39-9P 442561-43-5P
 442561-44-6P 442561-48-0P 442561-49-1P
 442561-52-6P 442561-53-7P 442561-54-8P
 442561-55-9P 442561-56-0P 442561-57-1P
 442561-58-2P 442561-59-3P 442561-60-6P
 442561-64-0P 442561-65-1P 442561-66-2P
 442561-67-3P 442561-68-4P 442561-71-9P
 442561-72-0P 442561-73-1P 442561-74-2P
 442561-75-3P 442561-76-4P 442561-77-5P
 442561-82-2P 442561-86-6P 442561-93-5P
 442561-94-6P 442562-00-7P 442562-01-8P
 442562-02-9P 442562-03-0P 442562-10-9P
 442562-15-4P 442562-16-5P 442655-34-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compd.; prepn. of (aryl)(pyrrolimethylene)indolinones as protein kinase signal transduction modulators)


RN 442558-05-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-(2-(diethylamino)ethyl)-5-[(1,2-dihydro-2-oxo-4-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-07-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-(2-(diethylamino)ethyl)-5-[(4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-08-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-09-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)


442558-11-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-15-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylamino)ethyl]-5-[(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-16-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-17-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-23-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)




RN 442558-24-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 442558-25-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-31-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)




RN 442558-32-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 442558-33-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-36-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-39-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-40-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)




RN 442558-41-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]-(9CI) (CA INDEX NAME)




RN 442558-43-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)




RN 442558-44-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]-(9CI) (CA INDEX NAME)




RN 442558-48-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-49-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)




RN 442558-50-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]-(9CI) (CA INDEX NAME)




RN 442558-52-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)




RN 442558-53-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-54-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(bis(1-methylethyl)amino)ethyl]-5-[(1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-56-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-57-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 442558-58-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-60-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-61-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-62-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(bis(1-methylethyl)amino)ethyl]-5-[(4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)





RN 442558-63-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-65-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-66-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-71-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(bis(1-methylethyl)amino)ethyl]-5-[(4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-72-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
N-(2-(diethylamino)ethyl)-5-[(4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)


RN 442558-67-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-69-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-70-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442558-73-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-74-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 5-[(4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-75-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 5-[(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-76-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
5-[(4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-77-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
5-[(4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-78-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-90-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-91-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-92-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-79-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-80-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-89-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-93-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-94-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-96-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-97-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl] (9CI) (CA INDEX NAME)




RN 442558-98-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl] (9CI) (CA INDEX NAME)




RN 442558-99-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-2-[(4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 442559-00-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl] (9CI) (CA INDEX NAME)




RN 442559-01-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl] (9CI) (CA INDEX NAME)




RN 442559-03-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442559-04-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl] (9CI) (CA INDEX NAME)




RN 442559-05-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442559-07-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442559-08-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 442559-09-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-(2-(1H-1,2,3-triazol-1-yl)ethyl)- (9CI) (CA INDEX NAME)




RN 442559-10-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylaminoethyl)-2-((1,2-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-3H-indol-3-ylidene)methyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 442559-11-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-((1,2-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-3H-indol-3-ylidene)methyl)-5-methyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 442559-12-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-((1,2-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-3H-indol-3-ylidene)methyl)-5-methyl-N-(2-(1H-1,2,3-triazol-1-yl)ethyl)- (9CI) (CA INDEX NAME)




RN 442559-14-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3-(diethylamino)propyl)-5-((1,2-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442559-15-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-((1,2-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-3H-indol-3-ylidene)methyl)-5-methyl-N-(3-(1-pyrrolidinyl)propyl)- (9CI) (CA INDEX NAME)




RN 442559-19-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-(diethylamino)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442559-20-8 CAPLUS

L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Pyrrole-3-carboxamide, 5-[(4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442559-21-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 442559-22-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 442559-23-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 442559-42-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-[(1,2-dihydro-2-oxo-4-(4-(trifluoromethoxy)phenyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 442559-43-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-4-(4-(trifluoromethoxy)phenyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442559-44-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(1,2-dihydro-2-oxo-4-(4-(trifluoromethoxy)phenyl)-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-45-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(1,2-dihydro-2-oxo-4-(4-(trifluoromethoxy)phenyl)-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 442559-46-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(1,2-dihydro-2-oxo-4-(4-(trifluoromethoxy)phenyl)-3H-indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 442559-53-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(2)-[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-54-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(2)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-55-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(2)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl-N-(1-methyl-4-piperidinyl)-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-57-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(2)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-58-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(2)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-59-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(2)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-60-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(2)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-79-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(2)-[1,2-dihydro-4-(3-(2-hydroxyethyl)phenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442559-80-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-{1,2-dihydro-4-[3-(2-hydroxyethyl)phenyl]-
2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-
yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-81-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(2)-{1,2-dihydro-4-[3-(2-hydroxyethyl)phenyl]-
2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-
yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442559-98-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-{4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-4-methyl-N-[3-(2-methyl-1-piperidinyl)propyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-99-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-{4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-4-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.


RN 442559-94-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(2)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-5-methyl-N-[1,2,3,6-tetrahydro-2,6-dioxo-4-
pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-97-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-4-methyl-N-[2-(4-morpholinyl)ethyl]- (CA
INDEX NAME)

Double bond geometry as shown.



RN 442560-00-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-4-methyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.




RN 442560-01-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-4-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.


RN 442560-02-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-03-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-4-methyl-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-17-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-4-(2-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-31-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-(4-(3-cyano-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-1,2,3-triazol-2-yl)propyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-04-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-16-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-4-(2-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-39-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-4-(1,1'-biphenyl)-3-yl-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-1,2,3-triazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-43-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-44-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-4-(1,1'-biphenyl)-2-yl-1,2-dihydro-2-oxo-
3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 442560-45-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-4-(1,1'-biphenyl)-2-yl-1,2-dihydro-2-oxo-
3H-indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 442560-46-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.




RN 442560-47-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.




RN 442560-48-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.




RN 442560-49-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.




RN 442560-51-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-4-(3,5-difluorophenyl)-1,2-dihydro-2-oxo-
3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-52-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-4-(3,5-difluorophenyl)-1,2-dihydro-2-oxo-
3H-indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 442560-59-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(2)-[1,2-dihydro-4-[3-(2-hydroxyethyl)phenyl]-
2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-64-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-N-methyl-N-(1-methyl-4-piperidinyl)-4-phenyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-65-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(2)-[4-(2-
fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-phenyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-66-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.




RN 442560-69-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(2)-[4-[3-(2-
dimethylamino)-2-oxethyl]phenyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-79-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-2,4-dimethyl-N-[(1,2,3,6-tetrahydro-2,6-dioxo-4-
pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-80-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-[4-(3-amino-1H-indazol-5-yl)-1,2-dihydro-
2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-81-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(2)-[4-(3-amino-1H-indazol-5-yl)-1,2-dihydro-
2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-83-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-{4-(2,3-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-(2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-88-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-{4-(2,4-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-89-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-{4-(2,4-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-01-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-{4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-02-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-{4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-04-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(4-acetyl-1-piperazinyl)ethyl]-2-[(Z)-{4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-05-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(4-acetyl-1-piperazinyl)ethyl]-2-[(Z)-{4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-06-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(4-acetyl-1-piperazinyl)ethyl]-5-[(Z)-{4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-07-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-1-(4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-08-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-1-(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-09-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-1-(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-10-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-1-(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-11-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-1-(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-12-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-1-(4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-13-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(Z)-1-(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-29-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-1-(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(4-(hydroxyacetyl)-1-piperazinyl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-31-1 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-
 3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(methylsulfonyl)propyl]- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-32-2 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-
 3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(methylsulfonyl)propyl]- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-39-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethoxy)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-43-5 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-
 3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-44-6 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 2-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-
 3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-48-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-49-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[4-(3,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-52-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-(methylamino)carbonyl]phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

Double bond geometry as shown.




RN 442561-53-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-((Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-54-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-5-((Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-



RN 442561-55-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-((Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-56-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-((Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-


L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 3H-indol-3-ylidene)methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2-fluoro-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-57-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-{4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-58-2 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-((Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-


L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-59-3 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 2-[(Z)-{4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-60-6 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[(Z)-{4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-64-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-[(Z)-{4-(3,5-difluorophenyl)-1,2-dihydro-2-oxo-


L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 3H-indol-3-ylidene)methyl)-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-5-methyl-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-65-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-((Z)-[4-(2,4-difluorophenyl)-1,2-dihydro-2-oxo-
 3H-indol-3-ylidene)methyl)-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-5-methyl-
 (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-66-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-((Z)-[4-(3-chloro-4-fluorophenyl)-1,2-dihydro-
 2-oxo-3H-indol-3-ylidene)methyl)-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-5-


L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-67-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-((Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-
 indol-3-ylidene)methyl)-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-5-methyl-
 (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-68-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-((Z)-[4-(2,3-difluorophenyl)-1,2-dihydro-2-oxo-
 3H-indol-3-ylidene)methyl)-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-5-methyl-
 (9CI) (CA INDEX NAME)


L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.



RN 442561-71-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-((Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-
 indol-3-ylidene)methyl]-5-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA
 INDEX NAME)


Double bond geometry as shown.



RN 442561-72-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-[(3-(acetylaminoo)-1-pyrrolidinyl)ethyl]-2-
 ((Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-
 methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L12 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 442561-73-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-((Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-
 indol-3-ylidene)methyl]-5-methyl-N-[(1-methyl-4-piperidinyl)methyl]-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-74-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 2-((Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-
 indol-3-ylidene)methyl)-N-[2-(4-hydroxy-1-piperidinyl)ethyl]-5-methyl-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-75-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(1-dioxido-4-thiomorpholinyl)-2-indol-3-ylidene]methyl-2-[(Z)-(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-76-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-(4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-77-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-{4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene}methyl]-N-(3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl)-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-82-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-((2,2,2-trifluoroethyl)amino)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-86-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
2-[(Z)-(4-(2,3-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-94-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(Z)-(4-(2,3-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442562-00-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
2-[(Z)-(4-(2,3-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442562-01-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 $2-(\{Z\}-(4-(3\text{-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-5\text{-ido-4-methyl-N-[3-(1-pyrrolidinyl)propyl]-}$
 $(9CI)$ (CA INDEX NAME)

Double bond geometry as shown.




RN 442562-02-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 $2-(\{Z\}-(4-(3\text{-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-(2S)-2\text{-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl}-5\text{-methyl-}$
 $(9CI)$ (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 442562-03-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 $2-(\{Z\}-(4-(3\text{-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-(\{2R\})-2\text{-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl}-5\text{-methyl-}$
 $(9CI)$ (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 442562-10-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 $N-(3-(cyclopropylamino)-2-hydroxypropyl)-2-(\{Z\}-(4-(2,3-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-$
 $methyl-$
 $(9CI)$ (CA INDEX NAME)

Double bond geometry as shown.




RN 442562-15-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 $2-(\{Z\}-(4-(3\text{-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-N-[2\text{-hydroxy-3-(1-pyrrolidinyl)propyl}-N,5-$
 dimethyl-
 $(9CI)$ (CA INDEX NAME)

Double bond geometry as shown.




RN 442562-16-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 $N-(3-(cyclopropylamino)-2-hydroxypropyl)-2-(\{Z\}-(4-(3\text{-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-5\text{-methyl-}$
 $(9CI)$ (CA INDEX NAME)

Double bond geometry as shown.



RN 442655-34-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 $2-(\{Z\}-(4-(2,3-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2\text{-hydroxy-3-(1-pyrrolidinyl)propyl}-N,5-$
 dimethyl-
 $(9CI)$ (CA INDEX NAME)


Double bond geometry as shown.



L12 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:31440 CAPLUS
 DOCUMENT NUMBER: 136:102386
 TITLE: Preparation and use of
 4-heteroaryl-3-heteroarylidene-
 2-indolinones and their use as protein kinase
 inhibitors
 INVENTOR(S): Tang, Peng Cho; Wei, Chung Chen; Huang, Ping; Cui,
 Jingcon
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 164 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200202551	A1	20020110	WO 2001-US20768	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CL, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414468	A1	20020110	CA 2001-2414468	20010629
US 2002187978	A1	20021212	US 2001-894902	20010629
US 6635640	B2	20031021		
EP 1296975	A1	20030429	EP 2001-948830	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502686	T2	20040129	JP 2002-507803	20010629
US 2004087497	A1	20040520	US 2003-648810	20030827
			US 2000-215654P	P 20000630
PRIORITY APPN. INFO.: US 2001-894902				
			WO 2001-US20768	W 20010629


OTHER SOURCE(S): MARPAT 136:102386
 GI




AB Title compds. I [R1=H, alkyl, cycloalkyl, aryl, heteroaryl,

L12 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 388116-64-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-68-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 388116-74-3 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene)methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 388116-96-9 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 heteroaromatic, halo, etc.; Het = (un)substituted arom. heterocycle contg. at least one and not more than two N atoms, tetrahydrothiopyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted arom. heterocycle contg. not more than two N atoms, 5-membered ring (un)substituted heterocycle contg. N or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.) with some exceptions, were prep'd. Included are 75 synthetic examples and results for several protein tyrosine kinase assays for those compds. For instance, 4-bromindole was coupled to bis(pinacolato)diborane (DMSO, KOAc, PdCl2(dppf):CH2Cl2, 80°C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine-HCl (THF, Pd(PPh3)4, NaOH, 70°C, 6 h) to give the indole which was treated with CS5N+Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1addnl. hour) to give 4-(pyridin-4-yl)-1,3-dihydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.88 nM for FGFR-1 tyrosine kinase and 0.03 nM for cdk2/cyclin A tyrosine kinase. I are useful in treating cancer, immunol. disorders, etc.


IT 388116-60-7P 388116-61-0P 388116-64-1P
 388116-68-5P 388116-74-3P 388116-96-9P
 388116-97-0P 388116-99-2P 388117-02-0P
 388117-06-4P 388117-08-6P 388117-10-0P
 388117-12-2P 388117-28-0P 388117-30-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation and use of
 4-heteroaryl-3-heteroarylidene-2-indolinones
 and their use as protein kinase inhibitors)


RN 388116-60-7 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 388116-61-8 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 2-[(1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)




L12 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 388116-97-0 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 2-[(1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 388116-99-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 388117-02-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 388117-06-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene)methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 388117-08-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene)methyl]-4-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 388117-10-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene)methyl]-4-methyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 388117-12-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene)methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 388117-28-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 388117-30-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:617993 CAPLUS
DOCUMENT NUMBER: 135:19549
TITLE: Preparation of pyrrole substituted 2-indolinone protein kinase inhibitors for treatment of cancer
INVENTOR(S): Tang, Peng Choi; Miller, Todd; Li, Xiaoyuan; Sun, Li; Wei, Chung Chen; Shirazian, Shahzad; Liang, Congxin; Vojkovsky, Tomas; Nemataila, Assad S.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 225 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060814	A2	20010823	WO 2001-US4813	20010215
WO 2001060814	A3	20020124		
W: AE, AG, AL, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, TU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RO, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2399358	AA	20010823	CA 2001-2399358	20010215
US 2002156292	A1	20021024	US 2001-783264	20010215
US 6573293	B2	20030603		
EP 1255752	A2	20021113	EP 2001-914376	20010215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523340	T2	20030805	JP 2001-560198	20010215
JP 3663382	B2	20050622		
BR 2001008394	A	20040622	BR 2001-8394	20010215
NZ 520640	A	20050429	NZ 2001-520640	20010215
NO 2002003831	A	20021015	NO 2002-3831	20020813
ZA 2002006469	A	20031113	ZA 2002-6469	20020813
BG 107076	A	20030430	BG 2002-107078	20020910
US 2004063773	A1	20040401	US 2003-412690	20030414
US 2005176802	A1	20050811	US 2005-28477	20050104
PRIORITY APPLN. INFO.:			US 2000-182710P	P 20000215
			US 2000-216422P	P 20000706
			US 2000-243532P	P 20001027
			US 2001-783264	A3 20010215
			WO 2001-AU4813	W 20010215
			WO 2001-US4813	W 20010215
			US 2003-412690	A1 20030414



I



II

AB The title compds. (I) [wherein R1 = H, halo, (cyclo)alkyl, (hetero)aryl, heterocyclic, OH, alkoxy, acyl, (un)substituted amino or carbamoyl, etc.; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (hetero)aryl, (un)substituted amino, acyl(amino), or sulfamoyl, etc.; R3 = H, halo, alkyl, trihalomethyl, OH, alkoxy, (hetero)aryl, (un)substituted acyl, (acyl)amino, sulfamoyl, or alkylsulfonyl, etc.; R4 = H, halo, alkyl, OH, alkoxy, or (un)substituted amino; R5 and R6 = independently H, alkyl, or acyl; R7 = H, alkyl, (hetero)aryl, or acyl; and their pharmaceutically acceptable salts] were prepared as protein kinase modulators for the treatment of cellular disorders such as cancer. For example, 5-fluoro-1,3-dihydroindol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminomethyl)amide to give II (55%). II exhibited comparable activity against Flk-1 and PDGFRB and inhibited PDGF-dependent receptor phosphorylation in cells with an IC₅₀ value of approx. 0.03 μM. In efficacy expts. against various cancers in mice, II was well tolerated at 80 mg/kg/day, even when dosed continuously for more than 100 days.


IT 356068-93-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrrole substituted 2-indolinone protein kinase inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 356068-93-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 557795-19-4P


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrole substituted 2-indolinone protein kinase

inhibitors
by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 557795-19-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl}-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 280740-39-2P 326914-09-4P 326914-10-7P


326914-17-4P 326914-19-6P 342641-15-0P
342641-17-2P 342641-18-3P 342641-19-4P
342641-20-7P 342641-21-8P 342641-22-9P
342641-23-0P 342641-24-1P 342641-25-2P
342641-26-3P 342641-27-4P 342641-28-5P
342641-33-2P 342641-35-4P 342641-36-5P
342641-37-6P 342641-38-7P 342641-39-8P
342641-40-1P 342641-41-2P 342641-42-3P
342641-43-4P 342641-44-5P 342641-45-6P
342641-46-7P 342641-47-8P 342641-48-9P
342641-49-0P 342641-50-3P 342641-51-4P
342641-52-5P 342641-54-7P 342641-55-8P
342641-56-9P 342641-57-0P 342641-59-2P
342641-60-5P 342641-61-6P 342641-62-7P
342641-63-8P 342641-64-9P 342641-65-0P
342641-66-1P 342641-67-2P 342641-68-3P
342641-69-4P 342641-70-7P 342641-71-8P
342641-72-9P 342641-73-0P 342641-74-1P
342641-75-2P 342641-76-3P 342641-77-4P
342641-78-5P 342641-79-6P 342641-80-9P
342641-81-0P 342641-82-1P 342641-83-2P
342641-84-3P 342641-85-4P 342641-87-6P
342641-88-7P 342641-89-8P 342641-91-2P

342641-92-3P 342641-93-4P 342641-94-5P
342641-95-6P 342641-96-7P 342641-97-8P
342641-98-9P 342642-01-7P 342642-02-8P
342642-03-9P 342642-05-5P 342642-10-0P
342642-11-1P 342642-12-2P 342642-15-3P
342642-16-4P 342642-17-5P 342640-32-1P
356068-92-1P 356068-90-1P 356068-91-2P
356068-92-3P 356068-94-5P 356068-95-6P
356068-96-7P 356068-97-8P 356068-99-0P
356069-03-0P 356069-04-0P 356069-05-1P
356069-07-3P 356069-09-5P 356069-12-0P
356069-13-5P 356069-15-3P 356069-16-4P
356069-17-5P 356069-18-6P 356069-19-7P
356069-20-0P 356069-21-1P 356069-22-2P
356069-23-3P 356069-24-4P 356069-25-5P
356069-26-6P 356069-27-7P 356069-28-8P
356069-29-9P 356069-30-0P 356069-31-1P
356069-33-5P 356069-34-6P 356069-35-7P
356069-36-0P 356069-37-0P 356069-39-0P
356069-39-3P 356069-40-4P 356069-44-5P
356069-42-6P 356069-43-7P 356069-44-8P
356069-45-9P 356069-46-0P 356069-47-1P
356069-48-2P 356069-49-3P 356069-50-4P
356069-51-5P 356069-52-6P 356069-55-1P
356069-57-3P 356069-58-4P 356069-59-5P
356069-60-6P 356069-61-7P 356069-62-8P
356069-64-2P 356069-65-3P 356069-66-4P
356069-67-5P 356069-68-6P 356069-69-7P
356069-70-0P 356069-71-1P 356069-72-2P
356069-73-3P 356069-74-4P 356069-75-5P
356069-76-6P 356069-77-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrole substituted 2-indolinone protein kinase inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 280748-39-4 CAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 5-[{(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 326914-09-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[{(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 326914-10-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 326914-17-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide,
N-[2-(dimethylamino)ethyl]-5-[{(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 326914-19-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[{(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 342641-15-0 CAPIUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-17-2 CAPIUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-18-3 CAPIUS
CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-N-(3-(1-pyrrolidinyl)propyl)- (9CI) (CA INDEX NAME)




RN 342641-19-4 CAPIUS
CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(3-(diethylamino)propyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-24-1 CAPIUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-25-2 CAPIUS
CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(3-(diethylamino)propyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-26-3 CAPIUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-27-4 CAPIUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-20-7 CAPIUS
CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-21-8 CAPIUS
CN 1H-Pyrrole-2-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 342641-22-9 CAPIUS
CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 342641-23-0 CAPIUS
CN 1H-Pyrrole-2-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 342641-28-5 CAPIUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-33-2 CAPIUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-35-4 CAPIUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




L12 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 342641-36-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 342641-37-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-38-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-39-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


L12 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-40-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-41-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-42-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)


L12 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 342641-43-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 342641-44-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-45-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(3-hydroxypropyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-46-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-


L12 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
3-ylidene)methyl]-3-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-47-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-48-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(4-hydroxyphenyl)ethyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-49-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-50-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2-(1-methylethyl)-4-phenyl-N-(3-(1-pyrrolidinyl)propyl)-(9CI) (CA INDEX NAME)




RN 342641-51-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(diethylamino)ethyl]-2-(1-methylethyl)-4-phenyl-(9CI) (CA INDEX NAME)




RN 342641-52-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2-(1-methylethyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl-(9CI) (CA INDEX NAME)




RN 342641-54-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2-methyl-4-phenyl-N-(2-(1-pyrrolidinyl)ethyl)-(9CI) (CA INDEX NAME)




RN 342641-55-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl)-2-methyl-4-phenyl-N-(2-(1-pyrrolidinyl)ethyl)-(9CI) (CA INDEX NAME)




RN 342641-56-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl-(9CI) (CA INDEX NAME)




RN 342641-57-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl-(9CI) (CA INDEX NAME)




RN 342641-59-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[3-(diethylamino)propyl]-2-methyl-4-phenyl-(9CI) (CA INDEX NAME)




RN 342641-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)




RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)




RN 342641-62-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)




RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-65-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-66-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-67-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-68-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-((1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-69-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-70-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl)-N-[2-(1-pyrrolidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-71-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-((1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-72-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-73-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(3H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-74-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)




RN 342641-75-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-76-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-77-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-78-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-79-6 CAPLUS




RN 342641-80-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-(3-(dimethylamino)propyl)-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-81-0 CAPLUS
CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[(4-[(3-(dimethylamino)propyl)amino]carbonyl)-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-83-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-84-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-85-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-87-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 342641-88-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-89-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxy-5-(1-methylethyl)phenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-91-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(6-(4-ethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-92-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-93-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(3-(1-methylethyl)phenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-95-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(4-[(2-(diethylamino)ethyl)amino]carbonyl)-3,5-dimethyl-1H-pyrrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-((dimethylamino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-((3-chlorophenyl)amino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-98-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-((3-pyridinylamino)sulfonyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342642-01-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-((dimethylamino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-02-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-((3-chlorophenyl)amino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-08-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342642-09-5 CAPLUS
CN Glycine, N-[(5-((1,2-dihydro-4-methyl-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl)-4-methyl-1H-pyrrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-10-8 CAPLUS
CN Glycine, N-[(5-((1,2-dihydro-4-methyl-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl)-4-methyl-1H-pyrrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-11-9 CAPLUS
CN Glycine, N-[(5-((1,2-dihydro-4-methyl-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl)-4-methyl-1H-pyrrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 342642-12-0 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 342642-15-3 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 342642-16-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342642-17-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 346405-32-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356068-82-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356068-90-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-91-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-92-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356068-94-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356068-95-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-96-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-97-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356068-99-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethyloxidoamino)ethyl]-5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 356069-03-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356069-04-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)



RN 356069-05-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356069-07-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-09-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-(3,5-dimethyl-1-piperazinyl)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-12-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-13-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-15-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L12 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1


CRN 356068-82-1
 CMF C22 H25 Cl N4 O2



CM 2

CRN 97-67-6
 CMF C4 H6 O5


Absolute stereochemistry. Rotation (-).




RN 356069-19-7 CAPLUS
 CN Butanedioic acid, hydroxy-, (2S)-, compd. with
 N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1


CRN 342641-94-5
 CMF C22 H27 F N4 O2



RN 356069-16-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(ethylaminoethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-17-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide,
 N-[2-(diethyloxidoaminoethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-18-6 CAPLUS
 CN Butanedioic acid, hydroxy-, (2S)-, compd. with
 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-


L12 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 97-67-6
 CMF C4 H6 O5


Absolute stereochemistry. Rotation (-).



RN 356069-20-0 CAPLUS
 CN Butanedioic acid, hydroxy-, (2S)-, compd. with
 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylaminoethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1


CRN 356068-90-1
 CMF C22 H27 Cl N4 O2



CM 2

CRN 97-67-6
 CMF C4 H6 O5


Absolute stereochemistry. Rotation (-).



RN 356069-21-1 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1


CRN 346405-32-1
CNF C22 H25 F N4 O2



CM 2

CRN 97-67-6
CNF C4 H6 O5


Absolute stereochemistry. Rotation (-).



RN 356069-22-2 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1


CRN 356069-16-4
CNF C20 H23 F N4 O2



CM 2

CRN 97-67-6
CNF C4 H6 O5

Absolute stereochemistry. Rotation (-).




RN 356069-23-3 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylaminoethyl)-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-99-0
CNF C22 H27 F N4 O3


Double bond geometry as shown.



CM 2


CRN 97-67-6
CNF C4 H6 O5

Absolute stereochemistry. Rotation (-).




RN 356069-24-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylaminio)ethyl]-5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-25-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylaminio)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-26-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylaminio)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-27-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-28-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-29-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-30-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-31-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-33-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-32-4
 CMF C22 H24 Br N5 O3


Double bond geometry as shown.



CM 2


L12 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-37-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-38-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-34-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-35-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-36-8 CAPLUS




RN 356069-39-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-40-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-41-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-42-6 CAPLUS
CN 1-Piperazineacetic acid, 4-[[5-((Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]- ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-43-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[[5-((Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]- ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-44-8 CAPLUS
CN 1-Piperazineacetic acid, 4-[[5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]- ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-45-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(cyanomethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-46-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-47-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-48-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-49-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-50-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-51-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-(acetylaminio)ethyl)-5-((Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-53-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-(2-(3-oxo-1-piperazinyl)ethyl)-mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-52-8
CMF C22 H24 F N5 O3


Double bond geometry as shown.



CM 2

CRN 356069-56-2
CMF C23 H24 N6 O3

Double bond geometry as shown.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 356069-58-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-((2-cyanoethyl)amino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-59-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-((2-cyanoethyl)amino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

CRN 76-05-1
CMF C2 H F3 O2




RN 356069-55-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-54-0
CMF C22 H25 N5 O3

Double bond geometry as shown.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 356069-57-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1




RN 356069-60-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-((2-cyanoethyl)amino)ethyl]-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-61-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-((2-cyanoethyl)amino)ethyl]-5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-62-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-((2-cyanoethyl)amino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-64-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

CM 1

CRN 356069-63-1
CMF C22 H24 Cl N5 O3

Double bond geometry as shown.




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 356069-65-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-68-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-69-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-70-0 CAPLUS



RN 356069-66-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-67-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L12 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-71-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-72-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-73-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-74-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-(phenylmethyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-75-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-(phenylmethyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-76-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-(phenylmethyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-77-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[(5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrrol-3-yl]carbonyl]amino]ethyl-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.




IT 342641-53-6 356069-06-2 356069-08-4
356069-10-8 356069-14-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of pyrrole substituted 2-indolinone protein kinase inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)
RN 342641-53-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 356069-06-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-08-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-10-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-14-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(2)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



L12 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:396655 CAPLUS
 DOCUMENT NUMBER: 135:19549
 TITLE: Preparation of pyrrole substituted 2-indolinones as antitumor agents
 INVENTOR(S): Shenoy, Narmada; Sorasuchart, Waranush
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 249 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037820	A2	20010531	WO 2000-US32277	20001122
WO 2001037820	A3	20011213		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CN, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6878733	B1	20050412	US 2000-716332	20001121
AU 2001019285	A5	20010604	AU 2001-19285	20001122
EP 1233943	A2	20020828	EP 2000-982228	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003514851	T2	20030422	JP 2001-539435	20001122
US 1999-167544P A1 19991124				
PRIORITY APPLN. INFO.: WO 2000-US32277 W 20001122				


OTHER SOURCE(S): MARPAT 135:19549
 GI




AB The title compds. {I: R1 = H, alkyl, alkenyl, etc.; R2 = H, halo, alkyl, etc.; R3-R6 = H, alkyl, trihaloalkyl, etc.; R3 and R4, R4 and R5, R5 and R6 may combine to form a six membered aryl ring, OCH2O, OCH2CH2O; R7 = H,

L12 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 342641-96-7P 342641-97-0P 342641-98-9P
 342642-01-7P 342642-02-0P 342642-08-4P
 342642-09-5P 342642-10-0P 342642-11-9P
 342642-12-0P 342642-15-3P 342642-16-4P
 342642-17-5P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of pyrrole substituted 2-indolinones as antitumor agents)


RN 280748-39-2 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 342641-15-0 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 342641-17-2 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 342641-18-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


L12 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 alkyl, cycloalkyl, etc.; R8-R10 = H, alkyl, trihaloalkyl, etc.] were prep'd. and formulated. E.g., a multi-step synthesis of I [R1-R7 = H; R8, R10 = Me; R9 = (CH₂)₂COZH] which showed 79-86% inhibition of tumor growth of Calu-6 cells in mice at 75 and 100 mg/kg/day, was given. The present invention features formulations of indolinones which compds. are

ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term "ionizable substituted indolinone" includes pyrrole substituted 2-indolinones I which, in addn. to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compd., are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group.

IT 342641-53-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrrole substituted 2-indolinones as antitumor agents)


RN 342641-53-6 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




IT 280748-39-2F 342641-15-0P 342641-17-2P
 342641-18-3P 342641-19-4P 342641-20-7P
 342641-21-8P 342641-22-9P 342641-23-0P
 342641-24-1P 342641-25-2P 342641-26-3P
 342641-27-4P 342641-28-5P 342641-33-2P
 342641-35-4P 342641-36-5P 342641-37-6P
 342641-38-7P 342641-39-8P 342641-40-1P
 342641-41-2P 342641-42-3P 342641-43-4P
 342641-44-5P 342641-45-6P 342641-46-7P
 342641-47-8P 342641-48-9P 342641-49-0P
 342641-50-3P 342641-51-4P 342641-52-5P
 342641-54-7P 342641-55-8P 342641-56-9P
 342641-57-0P 342641-59-2P 342641-60-3P
 342641-61-6P 342641-62-7P 342641-63-8P
 342641-64-9P 342641-65-0P 342641-66-1P
 342641-67-2P 342641-68-3P 342641-69-4P
 342641-70-7P 342641-71-8P 342641-72-9P
 342641-73-0P 342641-74-1P 342641-75-2P
 342641-76-3P 342641-77-4P 342641-78-5P
 342641-79-6P 342641-80-9P 342641-81-0P
 342641-82-1P 342641-83-2P 342641-84-3P
 342641-85-4P 342641-87-6P 342641-88-7P
 342641-89-8P 342641-91-2P 342641-92-3P
 342641-93-4P 342641-94-5P 342641-95-6P


L12 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 342641-19-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-20-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-21-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[2-(diethylaminoethyl)]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 342641-22-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 342641-23-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
N-[2-(diethylaminoethyl)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 342641-24-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-25-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-26-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-36-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-37-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-38-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-27-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-28-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-33-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-35-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-39-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-(3-(1-pyrrolidinyl)propyl)- (9CI) (CA INDEX NAME)




RN 342641-40-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-(3-(1-pyrrolidinyl)propyl)- (9CI) (CA INDEX NAME)




RN 342641-41-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-(3-(1-pyrrolidinyl)propyl)- (9CI) (CA INDEX NAME)





RN 342641-42-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-acetyl-5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-43-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-acetyl-5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-44-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-acetyl-5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-3-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 342641-49-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[3-(diethylamino)propyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-50-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2-(1-methylethyl)-4-phenyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-51-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(2-(diethylamino)ethyl)-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)


RN 342641-45-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-acetyl-5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-(3-hydroxypropyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-46-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-acetyl-5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-3-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-47-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-acetyl-5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-3-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-48-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-acetyl-5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[2-(4-hydroxyphenyl)ethyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-52-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-54-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-((5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-55-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-56-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-(dimethylamino)ethyl)-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-57-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-59-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-(dimethylamino)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-(2-(dimethylamino)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-62-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-(dimethylamino)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-(diethylamino)ethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-65-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-66-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-67-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-68-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylaminoethyl)-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-69-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-70-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-71-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylaminoethyl)-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-72-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-73-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-74-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-75-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylaminoethyl)-5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-76-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-77-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-78-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-79-6 CAPLUS


L12 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-80-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-81-0 CAPLUS
CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[(4-[(3-diethylamino)propyl]amino)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-84-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-85-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 342641-88-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxy-5-(1-methylethyl)phenyl)-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(3-(1-methylethyl)phenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-95-6 CAPLUS
CN 1H-Indole-6-carboxylic acid,
3-[(4-[(2-(diethylamino)ethyl)amino]carbonyl)-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-(dimethylamino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 342641-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-((3-chlorophenyl)amino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-98-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342642-01-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-((3-chlorophenyl)amino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-02-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-((3-chlorophenyl)amino)sulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-08-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-4-methyl- (9CI) (CA INDEX NAME)




RN 342642-09-5 CAPLUS
CN Glycine, N-[(5-((1,2-dihydro-4-methyl-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-10-8 CAPLUS
CN Glycine, N-[(5-((1,2-dihydro-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-11-9 CAPLUS
CN Glycine, N-[(5-((1,2-dihydro-5-((methylamino)sulfonyl)-2-oxo-3H-indol-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 342642-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-[(5-methyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 342642-15-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 342642-16-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)



RN 342642-17-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-(diethylamino)ethyl)-5-methyl- (9CI) (CA INDEX NAME)



IT 342642-45-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrrole substituted 2-indolinones as antitumor agents)
 RN 342642-45-9 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)



```
=> fil casreact
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY        SESSION
FULL ESTIMATED COST          91.62         449.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE      TOTAL
                                                ENTRY        SESSION
CA SUBSCRIBER PRICE           -13.14         -13.14
```

FILE 'CASREACT' ENTERED AT 08:48:49 ON 08 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 4 Dec 2005 VOL 143 ISS 23



New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*****
*                                     *
*      CASREACT now has more than 10 million reactions   *
*                                     *
*****
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10656907.str
```



chain nodes :

10 11 12 14 15 16 26 27 28 29 30 31

ring nodes :

1 2 3 4 5 6 7 8 9 17 18 19 20 21 22 23 24 25

chain bonds :

7-11 8-10 11-12 12-14 14-15 14-16 23-27 24-26 27-28 28-29 29-30 29-31

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 17-18 17-22 18-19 19-20 20-21
21-22 21-23 22-25 23-24 24-25

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-11 8-9 8-10 11-12 12-14 14-15
14-16 17-18 17-22 18-19 19-20 20-21 21-22 21-23 22-25 23-24 23-27 24-25
24-26 27-28 28-29 29-30 29-31

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:Atom 29:CLASS
30:CLASS 31:CLASS

fragments assigned product role:

containing 1

fragments assigned reactant/reagent role:

containing 17

Element Count :

Node 12: Limited

C,C4

N,N1

O,OO

S,S0

L13 STRUCTURE UPLOADED

=> d

L13 HAS NO ANSWERS

L13 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 113

SAMPLE SEARCH INITIATED 08:49:25 FILE 'CASREACT'

SCREENING COMPLETE - 105 REACTIONS TO VERIFY FROM 24 DOCUMENTS

100.0% DONE 105 VERIFIED 0 HIT RXNS 0 DOCS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED VERIFICATIONS: 1486 TO 2714

PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L13 (0 REACTIONS)

=> s 113 full

FULL SEARCH INITIATED 08:49:28 FILE 'CASREACT'

SCREENING COMPLETE - 5497 REACTIONS TO VERIFY FROM 461 DOCUMENTS

100.0% DONE 5497 VERIFIED 0 HIT RXNS 0 DOCS
SEARCH TIME: 00.00.01

L15 0 SEA SSS FUL L13 (0 REACTIONS)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
----------------------	------------------	---------------

FULL ESTIMATED COST	106.53	556.41
---------------------	--------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
--	------------------	---------------

CA SUBSCRIBER PRICE	0.00	-13.14
---------------------	------	--------

STN INTERNATIONAL LOGOFF AT 08:49:32 ON 08 DEC 2005